Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian
Disorders: Where do we go from here?

Félix-Antoine      Savoie; David   J.   Arpin; David   E.   Vaillancourt
doi:10.2174/1570159X21666230801140648
Abstract

Parkinsonian disorders are a heterogeneous group of incurable neurodegenerative diseases that significantly reduce quality of life and constitute a substantial economic burden. Nuclear imaging (NI) and magnetic resonance imaging (MRI) have played and continue to play a key role in research aimed at understanding and monitoring these disorders. MRI is cheaper, more accessible, nonirradiating, and better at measuring biological structures and hemodynamics than NI. NI, on the other hand, can track molecular processes, which may be crucial for the development of efficient diseasemodifying therapies. Given the strengths and weaknesses of NI and MRI, how can they best be applied to Parkinsonism research going forward? This review aims to examine the effectiveness of NI and MRI in three areas of Parkinsonism research (differential diagnosis, prodromal disease identification, and disease monitoring) to highlight where they can be most impactful. Based on the available literature, MRI can assist with differential diagnosis, prodromal disease identification, and disease monitoring as well as NI. However, more work is needed, to confirm the value of MRI for monitoring prodromal disease and predicting phenoconversion. Although NI can complement or be a substitute for MRI in all the areas covered in this review, we believe that its most meaningful impact will emerge once reliable Parkinsonian proteinopathy tracers become available. Future work in tracer development and high-field imaging will continue to influence the landscape for NI and MRI.
Keywords: Parkinson’s disease, magnetic resonance imaging, nuclear imaging, cerebral blood flow, MSA, corticobasal degeneration.
« Previous Next »
Graphical Abstract

[1]
Bloem, B.R.; Okun, M.S.; Klein, C. Parkinson’s disease. Lancet,  2021, 397(10291), 2284-2303.
 [http://dx.doi.org/10.1016/S0140-6736(21)00218-X] [PMID: 33848468]

[2]
Ahmed, Z.; Asi, Y.T.; Sailer, A.; Lees, A.J.; Houlden, H.; Revesz, T.; Holton, J.L. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol.,  2012, 38(1), 4-24.
 [http://dx.doi.org/10.1111/j.1365-2990.2011.01234.x] [PMID: 22074330]

[3]
Dickson, D.W.; Ahmed, Z.; Algom, A.A.; Tsuboi, Y.; Josephs, K.A. Neuropathology of variants of progressive supranuclear palsy. Curr. Opin. Neurol.,  2010, 23(4), 394-400.
 [http://dx.doi.org/10.1097/WCO.0b013e32833be924] [PMID: 20610990]

[4]
Dickson, D.W.; Bergeron, C.; Chin, S.S.; Duyckaerts, C.; Horoupian, D.; Ikeda, K.; Jellinger, K.; Lantos, P.L.; Lippa, C.F.; Mirra, S.S.; Tabaton, M.; Vonsattel, J.P.; Wakabayashi, K.; Litvan, I. Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol.,  2002, 61(11), 935-946.
 [http://dx.doi.org/10.1093/jnen/61.11.935] [PMID: 12430710]

[5]
Fearnley, J.M.; Lees, A.J. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain,  1991, 114(5), 2283-2301.
 [http://dx.doi.org/10.1093/brain/114.5.2283] [PMID: 1933245]

[6]
Oyanagi, K.; Tsuchiya, K.; Yamazaki, M.; Ikeda, K. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: Specific pathological features. J. Neuropathol. Exp. Neurol.,  2001, 60(4), 393-402.
 [http://dx.doi.org/10.1093/jnen/60.4.393] [PMID: 11305875]

[7]
Ozawa, T.; Paviour, D.; Quinn, N.P.; Josephs, K.A.; Sangha, H.; Kilford, L.; Healy, D.G.; Wood, N.W.; Lees, A.J.; Holton, J.L.; Revesz, T. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: Clinicopathological correlations. Brain,  2004, 127(12), 2657-2671.
 [http://dx.doi.org/10.1093/brain/awh303] [PMID: 15509623]

[8]
Kordower, J.H.; Olanow, C.W.; Dodiya, H.B.; Chu, Y.; Beach, T.G.; Adler, C.H.; Halliday, G.M.; Bartus, R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain,  2013, 136(8), 2419-2431.
 [http://dx.doi.org/10.1093/brain/awt192] [PMID: 23884810]

[9]
Piggott, M.A.; Marshall, E.F.; Thomas, N.; Lloyd, S.; Court, J.A.; Jaros, E.; Burn, D.; Johnson, M.; Perry, R.H.; McKeith, I.G.; Ballard, C.; Perry, E.K. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: Rostrocaudal distribution. Brain,  1999, 122(8), 1449-1468.
 [http://dx.doi.org/10.1093/brain/122.8.1449] [PMID: 10430831]

[10]
Thomas, A.J.; Attems, J.; Colloby, S.J.; O’Brien, J.T.; McKeith, I.; Walker, R.; Lee, L.; Burn, D.; Lett, D.J.; Walker, Z. Autopsy validation of 123 I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology,  2017, 88(3), 276-283.
 [http://dx.doi.org/10.1212/WNL.0000000000003512] [PMID: 27940650]

[11]
Saeed, U.; Lang, A.E.; Masellis, M. Neuroimaging advances in Parkinson’s Disease and atypical parkinsonian syndromes. Front. Neurol.,  2020, 11, 572976.
 [http://dx.doi.org/10.3389/fneur.2020.572976] [PMID: 33178113]

[12]
Roncevic, D.; Palma, J.A.; Martinez, J.; Goulding, N.; Norcliffe-Kaufmann, L.; Kaufmann, H. Cerebellar and parkinsonian phenotypes in multiple system atrophy: Similarities, differences and survival. J. Neural Transm. (Vienna),  2014, 121(5), 507-512.
 [http://dx.doi.org/10.1007/s00702-013-1133-7] [PMID: 24337696]

[13]
Williams, D.R.; de Silva, R.; Paviour, D.C.; Pittman, A.; Watt, H.C.; Kilford, L.; Holton, J.L.; Revesz, T.; Lees, A.J. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain,  2005, 128(6), 1247-1258.
 [http://dx.doi.org/10.1093/brain/awh488] [PMID: 15788542]

[14]
Deuschl, G.; Beghi, E.; Fazekas, F.; Varga, T.; Christoforidi, K.A.; Sipido, E.; Bassetti, C.L.; Vos, T.; Feigin, V.L. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health,  2020, 5(10), e551-e567.
 [http://dx.doi.org/10.1016/S2468-2667(20)30190-0] [PMID: 33007212]

[15]
Savica, R.; Grossardt, B.R.; Bower, J.H.; Boeve, B.F.; Ahlskog, J.E.; Rocca, W.A. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol.,  2013, 70(11), 1396-1402.
 [http://dx.doi.org/10.1001/jamaneurol.2013.3579] [PMID: 24042491]

[16]
Tysnes, O.B.; Storstein, A. Epidemiology of Parkinson’s disease. J. Neural Transm. (Vienna),  2017, 124(8), 901-905.
 [http://dx.doi.org/10.1007/s00702-017-1686-y] [PMID: 28150045]

[17]
Winter, Y.; Bezdolnyy, Y.; Katunina, E.; Avakjan, G.; Reese, J.P.; Klotsche, J.; Oertel, W.H.; Dodel, R.; Gusev, E. Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Mov. Disord.,  2010, 25(3), 349-356.
 [http://dx.doi.org/10.1002/mds.22966] [PMID: 20108378]

[18]
Bower, J.H.; Maraganore, D.M.; McDonnell, S.K.; Rocca, W.A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology,  1997, 49(5), 1284-1288.
 [http://dx.doi.org/10.1212/WNL.49.5.1284] [PMID: 9371909]

[19]
Mahapatra, R.K.; Edwards, M.J.; Schott, J.M.; Bhatia, K.P. Corticobasal degeneration. Lancet Neurol.,  2004, 3(12), 736-743.
 [http://dx.doi.org/10.1016/S1474-4422(04)00936-6] [PMID: 15556806]

[20]
Schrag, A.; Wenning, G.K.; Quinn, N.; Ben-Shlomo, Y. Survival in multiple system atrophy. Mov. Disord.,  2008, 23(2), 294-296.
 [http://dx.doi.org/10.1002/mds.21839] [PMID: 18044727]

[21]
Xie, T.; Yuen, C.A.; Kang, W.; Padmanaban, M.; Hain, T.C.; Nichols, J. Severity of downgaze palsy in the context of disease duration could estimate survival duration in patients with progressive supranuclear palsy. Front. Neurol.,  2021, 12, 736784.
 [http://dx.doi.org/10.3389/fneur.2021.736784] [PMID: 34650511]

[22]
Wenning, G.K.; Litvan, I.; Jankovic, J.; Granata, R.; Mangone, C.A.; McKee, A.; Poewe, W.; Jellinger, K.; Chaudhuri, K.R.; D’Olhaberriague, L.; Pearce, R.K.B. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J. Neurol. Neurosurg. Psychiatry,  1998, 64(2), 184-189.
 [http://dx.doi.org/10.1136/jnnp.64.2.184] [PMID: 9489528]

[23]
Coyle-Gilchrist, I.T.S.; Dick, K.M.; Patterson, K.; Vázquez Rodríquez, P.; Wehmann, E.; Wilcox, A.; Lansdall, C.J.; Dawson, K.E.; Wiggins, J.; Mead, S.; Brayne, C.; Rowe, J.B. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology,  2016, 86(18), 1736-1743.
 [http://dx.doi.org/10.1212/WNL.0000000000002638] [PMID: 27037234]

[24]
Goetz, C.G.; Tilley, B.C.; Shaftman, S.R.; Stebbins, G.T.; Fahn, S.; Martinez-Martin, P.; Poewe, W.; Sampaio, C.; Stern, M.B.; Dodel, R.; Dubois, B.; Holloway, R.; Jankovic, J.; Kulisevsky, J.; Lang, A.E.; Lees, A.; Leurgans, S.; LeWitt, P.A.; Nyenhuis, D.; Olanow, C.W.; Rascol, O.; Schrag, A.; Teresi, J.A.; van Hilten, J.J.; LaPelle, N. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov. Disord.,  2008, 23(15), 2129-2170.
 [http://dx.doi.org/10.1002/mds.22340] [PMID: 19025984]

[25]
Wenning, G.K.; Tison, F.; Seppi, K.; Sampaio, C.; Diem, A.; Yekhlef, F.; Ghorayeb, I.; Ory, F.; Galitzky, M.; Scaravilli, T.; Bozi, M.; Colosimo, C.; Gilman, S.; Shults, C.W.; Quinn, N.P.; Rascol, O.; Poewe, W. Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord.,  2004, 19(12), 1391-1402.
 [http://dx.doi.org/10.1002/mds.20255] [PMID: 15452868]

[26]
Golbe, L.I.; Ohman-Strickland, P.A. A clinical rating scale for progressive supranuclear palsy. Brain,  2007, 130(6), 1552-1565.
 [http://dx.doi.org/10.1093/brain/awm032] [PMID: 17405767]

[27]
Grötsch, M.T.; Respondek, G.; Colosimo, C.; Compta, Y.; Corvol, J.C.; Ferreira, J.; Huber, M.K.; Klietz, M.; Krey, L.F.M.; Levin, J.; Jecmenica-Lukic, M.; Macías-García, D.; Meissner, W.G.; Mir, P.; Morris, H.; Nilsson, C.; Rowe, J.B.; Seppi, K.; Stamelou, M.; Swieten, J.C.; Wenning, G.; Del Ser, T.; Golbe, L.I.; Höglinger, G.U. Describe PSP Study Group. the ProPSP Study Group, and the Movement Disorder Society-Endorsed PSP Study Group. A modified progressive supranuclear palsy rating scale. Mov. Disord.,  2021, 36(5), 1203-1215.
 [http://dx.doi.org/10.1002/mds.28470] [PMID: 33513292]

[28]
Lang, A.E.; Stebbins, G.T.; Wang, P.; Jabbari, E.; Lamb, R.; Morris, H.; Boxer, A.L. PROSPECT-M-UK investigators. The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism Relat. Disord.,  2020, 79, 121-126.
 [http://dx.doi.org/10.1016/j.parkreldis.2020.08.021] [PMID: 32947108]

[29]
Chougar, L.; Pyatigorskaya, N.; Degos, B.; Grabli, D.; Lehéricy, S. The role of magnetic resonance imaging for the diagnosis of atypical parkinsonism. Front. Neurol.,  2020, 11, 665.
 [http://dx.doi.org/10.3389/fneur.2020.00665] [PMID: 32765399]

[30]
Strafella, A.P.; Bohnen, N.I.; Pavese, N.; Vaillancourt, D.E.; Eimeren, T.; Politis, M.; Tessitore, A.; Ghadery, C.; Lewis, S. IPMDS‐Neuroimaging Study Group. Imaging Markers of Progression in Parkinson’s Disease. Mov. Disord. Clin. Pract. (Hoboken),  2018, 5(6), 586-596.
 [http://dx.doi.org/10.1002/mdc3.12673] [PMID: 30637278]

[31]
Yang, J.; Burciu, R.G.; Vaillancourt, D.E. Longitudinal progression markers of Parkinson’s Disease: Current view on structural imaging. Curr. Neurol. Neurosci. Rep.,  2018, 18(12), 83.
 [http://dx.doi.org/10.1007/s11910-018-0894-7] [PMID: 30280267]

[32]
Lehericy, S.; Vaillancourt, D.E.; Seppi, K.; Monchi, O.; Rektorova, I.; Antonini, A.; McKeown, M.J.; Masellis, M.; Berg, D.; Rowe, J.B.; Lewis, S.J.G.; Williams-Gray, C.H.; Tessitore, A.; Siebner, H.R.; International, P. International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Mov. Disord.,  2017, 32(4), 510-525.
 [http://dx.doi.org/10.1002/mds.26968] [PMID: 28370449]

[33]
Mitchell, T.; Lehéricy, S.; Chiu, S.Y.; Strafella, A.P.; Stoessl, A.J.; Vaillancourt, D.E. Emerging neuroimaging biomarkers across disease stage in Parkinson Disease. JAMA Neurol.,  2021, 78(10), 1262-1272.
 [http://dx.doi.org/10.1001/jamaneurol.2021.1312] [PMID: 34459865]

[34]
Vaquero, J.J.; Kinahan, P. Positron emission tomography: Current challenges and opportunities for technological advances in clinical and preclinical imaging systems. Annu. Rev. Biomed. Eng.,  2015, 17(1), 385-414.
 [http://dx.doi.org/10.1146/annurev-bioeng-071114-040723] [PMID: 26643024]

[35]
Accorsi, R. Brain single-photon emission CT physics principles. AJNR Am. J. Neuroradiol.,  2008, 29(7), 1247-1256.
 [http://dx.doi.org/10.3174/ajnr.A1175] [PMID: 18583408]

[36]
Gilman, S.; Wenning, G.K.; Low, P.A.; Brooks, D.J.; Mathias, C.J.; Trojanowski, J.Q.; Wood, N.W.; Colosimo, C.; Dürr, A.; Fowler, C.J.; Kaufmann, H.; Klockgether, T.; Lees, A.; Poewe, W.; Quinn, N.; Revesz, T.; Robertson, D.; Sandroni, P.; Seppi, K.; Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology,  2008, 71(9), 670-676.
 [http://dx.doi.org/10.1212/01.wnl.0000324625.00404.15] [PMID: 18725592]

[37]
Höglinger, G.U.; Respondek, G.; Stamelou, M.; Kurz, C.; Josephs, K.A.; Lang, A.E.; Mollenhauer, B.; Müller, U.; Nilsson, C.; Whitwell, J.L.; Arzberger, T.; Englund, E.; Gelpi, E.; Giese, A.; Irwin, D.J.; Meissner, W.G.; Pantelyat, A.; Rajput, A.; van Swieten, J.C.; Troakes, C.; Antonini, A.; Bhatia, K.P.; Bordelon, Y.; Compta, Y.; Corvol, J.C.; Colosimo, C.; Dickson, D.W.; Dodel, R.; Ferguson, L.; Grossman, M.; Kassubek, J.; Krismer, F.; Levin, J.; Lorenzl, S.; Morris, H.R.; Nestor, P.; Oertel, W.H.; Poewe, W.; Rabinovici, G.; Rowe, J.B.; Schellenberg, G.D.; Seppi, K.; van Eimeren, T.; Wenning, G.K.; Boxer, A.L.; Golbe, L.I.; Litvan, I. Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord.,  2017, 32(6), 853-864.
 [http://dx.doi.org/10.1002/mds.26987] [PMID: 28467028]

[38]
Postuma, R.B.; Berg, D.; Stern, M.; Poewe, W.; Olanow, C.W.; Oertel, W.; Obeso, J.; Marek, K.; Litvan, I.; Lang, A.E.; Halliday, G.; Goetz, C.G.; Gasser, T.; Dubois, B.; Chan, P.; Bloem, B.R.; Adler, C.H.; Deuschl, G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord.,  2015, 30(12), 1591-1601.
 [http://dx.doi.org/10.1002/mds.26424] [PMID: 26474316]

[39]
Armstrong, M.J.; Litvan, I.; Lang, A.E.; Bak, T.H.; Bhatia, K.P.; Borroni, B.; Boxer, A.L.; Dickson, D.W.; Grossman, M.; Hallett, M.; Josephs, K.A.; Kertesz, A.; Lee, S.E.; Miller, B.L.; Reich, S.G.; Riley, D.E.; Tolosa, E.; Tröster, A.I.; Vidailhet, M.; Weiner, W.J. Criteria for the diagnosis of corticobasal degeneration. Neurology,  2013, 80(5), 496-503.
 [http://dx.doi.org/10.1212/WNL.0b013e31827f0fd1] [PMID: 23359374]

[40]
Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry,  1992, 55(3), 181-184.
 [http://dx.doi.org/10.1136/jnnp.55.3.181] [PMID: 1564476]

[41]
Joutsa, J.; Gardberg, M.; Röyttä, M.; Kaasinen, V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat. Disord.,  2014, 20(8), 840-844.
 [http://dx.doi.org/10.1016/j.parkreldis.2014.04.019] [PMID: 24816002]

[42]
Koga, S.; Aoki, N.; Uitti, R.J.; van Gerpen, J.A.; Cheshire, W.P.; Josephs, K.A.; Wszolek, Z.K.; Langston, J.W.; Dickson, D.W. When DLB, PD, and PSP masquerade as MSA. Neurology,  2015, 85(5), 404-412.
 [http://dx.doi.org/10.1212/WNL.0000000000001807] [PMID: 26138942]

[43]
Rizzo, G.; Copetti, M.; Arcuti, S.; Martino, D.; Fontana, A.; Logroscino, G. Accuracy of clinical diagnosis of Parkinson disease. Neurology,  2016, 86(6), 566-576.
 [http://dx.doi.org/10.1212/WNL.0000000000002350] [PMID: 26764028]

[44]
Adler, C.H.; Beach, T.G.; Hentz, J.G.; Shill, H.A.; Caviness, J.N.; Driver-Dunckley, E.; Sabbagh, M.N.; Sue, L.I.; Jacobson, S.A.; Belden, C.M.; Dugger, B.N. Low clinical diagnostic accuracy of early vs. advanced Parkinson disease: Clinicopathologic study. Neurology,  2014, 83(5), 406-412.
 [http://dx.doi.org/10.1212/WNL.0000000000000641] [PMID: 24975862]

[45]
Eckert, T.; Barnes, A.; Dhawan, V.; Frucht, S.; Gordon, M.F.; Feigin, A.S.; Eidelberg, D. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage,  2005, 26(3), 912-921.
 [http://dx.doi.org/10.1016/j.neuroimage.2005.03.012] [PMID: 15955501]

[46]
Meyer, P.T.; Frings, L.; Rücker, G.; Hellwig, S. 18 F-FDG PET in Parkinsonism: Differential diagnosis and evaluation of cognitive impairment. J. Nucl. Med.,  2017, 58(12), 1888-1898.
 [http://dx.doi.org/10.2967/jnumed.116.186403] [PMID: 28912150]

[47]
Brajkovic, L.; Kostic, V.; Sobic-Saranovic, D.; Stefanova, E.; Jecmenica-Lukic, M.; Jesic, A.; Stojiljkovic, M.; Odalovic, S.; Gallivanone, F.; Castiglioni, I.; Radovic, B.; Trajkovic, G.; Artiko, V. The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurol. Res.,  2017, 39(8), 675-684.
 [http://dx.doi.org/10.1080/01616412.2017.1312211] [PMID: 28378615]

[48]
Hellwig, S.; Amtage, F.; Kreft, A.; Buchert, R.; Winz, O.H.; Vach, W.; Spehl, T.S.; Rijntjes, M.; Hellwig, B.; Weiller, C.; Winkler, C.; Weber, W.A.; Tuscher, O.; Meyer, P.T. [(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology,  2012, 79(13), 1314-1322.
 [http://dx.doi.org/10.1212/WNL.0b013e31826c1b0a] [PMID: 22914831]

[49]
Tripathi, M.; Dhawan, V.; Peng, S.; Kushwaha, S.; Batla, A.; Jaimini, A.; D’Souza, M.M.; Sharma, R.; Saw, S.; Mondal, A. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology,  2013, 55(4), 483-492.
 [http://dx.doi.org/10.1007/s00234-012-1132-7] [PMID: 23314836]

[50]
Caminiti, S.P.; Alongi, P.; Majno, L.; Volontè, M.A.; Cerami, C.; Gianolli, L.; Comi, G.; Perani, D. Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur. J. Neurol.,  2017, 24(5), 687-e26.
 [http://dx.doi.org/10.1111/ene.13269] [PMID: 28244178]

[51]
Tang, C.C.; Poston, K.L.; Eckert, T.; Feigin, A.; Frucht, S.; Gudesblatt, M.; Dhawan, V.; Lesser, M.; Vonsattel, J.P.; Fahn, S.; Eidelberg, D. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol.,  2010, 9(2), 149-158.
 [http://dx.doi.org/10.1016/S1474-4422(10)70002-8] [PMID: 20061183]

[52]
Tripathi, M.; Tang, C.C.; Feigin, A.; De Lucia, I.; Nazem, A.; Dhawan, V.; Eidelberg, D. Automated differential diagnosis of early parkinsonism using metabolic brain networks: A validation study. J. Nucl. Med.,  2016, 57(1), 60-66.
 [http://dx.doi.org/10.2967/jnumed.115.161992] [PMID: 26449840]

[53]
Brumberg, J.; Isaias, I.U. SPECT molecular imaging in atypical parkinsonism. Int. Rev. Neurobiol.,  2018, 142, 37-65.
 [http://dx.doi.org/10.1016/bs.irn.2018.08.006] [PMID: 30409259]

[54]
Borghammer, P.; Chakravarty, M.; Jonsdottir, K.Y.; Sato, N.; Matsuda, H.; Ito, K.; Arahata, Y.; Kato, T.; Gjedde, A. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: Probably even at early disease stages. Brain Struct. Funct.,  2010, 214(4), 303-317.
 [http://dx.doi.org/10.1007/s00429-010-0246-0] [PMID: 20361208]

[55]
Alster, P.; Nieciecki, M.; Koziorowski, D.; Cacko, A.; Charzyńska, I.; Królicki, L.; Friedman, A. Is brain perfusion a differentiating feature in the comparison of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)? J. Clin. Neurosci.,  2020, 77, 123-127.
 [http://dx.doi.org/10.1016/j.jocn.2020.05.005] [PMID: 32389545]

[56]
Kobayashi, Z.; Akaza, M.; Ishihara, S.; Tomimitsu, H.; Inadome, Y.; Arai, T.; Akiyama, H.; Shintani, S. Thalamic hypoperfusion in early stage of progressive supranuclear palsy(Richardson’s syndrome): Report of an autopsy-confirmed case. J. Neurol. Sci.,  2013, 335(1-2), 224-227.
 [http://dx.doi.org/10.1016/j.jns.2013.09.005] [PMID: 24075472]

[57]
Varrone, A.; Pagani, M.; Salvatore, E.; Salmaso, D.; Sansone, V.; Amboni, M.; Nobili, F.; De Michele, G.; Filla, A.; Barone, P.; Pappatà, S.; Salvatore, M. Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson’s disease. Eur. J. Nucl. Med. Mol. Imaging,  2007, 34(7), 1071-1081.
 [http://dx.doi.org/10.1007/s00259-006-0344-7] [PMID: 17245531]

[58]
Kimura, N.; Hanaki, S.; Masuda, T.; Hanaoka, T.; Hazama, Y.; Okazaki, T.; Arakawa, R.; Kumamoto, T. Brain perfusion differences in Parkinsonian disorders. Mov. Disord.,  2011, 26(14), 2530-2537.
 [http://dx.doi.org/10.1002/mds.23915] [PMID: 21830234]

[59]
Murakami, N.; Sako, W.; Haji, S.; Furukawa, T.; Otomi, Y.; Otsuka, H.; Izumi, Y.; Harada, M.; Kaji, R. Differences in cerebellar perfusion between Parkinson’s disease and multiple system atrophy. J. Neurol. Sci.,  2020, 409, 116627.
 [http://dx.doi.org/10.1016/j.jns.2019.116627] [PMID: 31865188]

[60]
Alster, P.; Nieciecki, M.; Koziorowski, D.M.; Cacko, A.; Charzyńska, I.; Królicki, L.; Friedman, A. Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine (Baltimore),  2019, 98(30), e16603.
 [http://dx.doi.org/10.1097/MD.0000000000016603] [PMID: 31348305]

[61]
Quattrone, A.; Nicoletti, G.; Messina, D.; Fera, F.; Condino, F.; Pugliese, P.; Lanza, P.; Barone, P.; Morgante, L.; Zappia, M.; Aguglia, U.; Gallo, O. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology,  2008, 246(1), 214-221.
 [http://dx.doi.org/10.1148/radiol.2453061703] [PMID: 17991785]

[62]
Matsuura, K.; Ii, Y.; Maeda, M.; Tabei, K.; Satoh, M.; Umino, M.; Miyashita, K.; Ishikawa, H.; Shindo, A.; Tomimoto, H. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia. Parkinsonism Relat. Disord.,  2021, 87, 75-81.
 [http://dx.doi.org/10.1016/j.parkreldis.2021.05.002] [PMID: 34000497]

[63]
Nigro, S.; Antonini, A.; Vaillancourt, D.E.; Seppi, K.; Ceravolo, R.; Strafella, A.P.; Augimeri, A.; Quattrone, A.; Morelli, M.; Weis, L.; Fiorenzato, E.; Biundo, R.; Burciu, R.G.; Krismer, F.; McFarland, N.R.; Mueller, C.; Gizewski, E.R.; Cosottini, M.; Del Prete, E.; Mazzucchi, S.; Quattrone, A. Automated MRI classification in progressive supranuclear palsy: A large international cohort study. Mov. Disord.,  2020, 35(6), 976-983.
 [http://dx.doi.org/10.1002/mds.28007] [PMID: 32092195]

[64]
Mangesius, S.; Hussl, A.; Krismer, F.; Mahlknecht, P.; Reiter, E.; Tagwercher, S.; Djamshidian, A.; Schocke, M.; Esterhammer, R.; Wenning, G.; Müller, C.; Scherfler, C.; Gizewski, E.R.; Poewe, W.; Seppi, K. MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism Relat. Disord.,  2018, 46, 47-55.
 [http://dx.doi.org/10.1016/j.parkreldis.2017.10.020] [PMID: 29126761]

[65]
Morelli, M.; Arabia, G.; Salsone, M.; Novellino, F.; Giofrè, L.; Paletta, R.; Messina, D.; Nicoletti, G.; Condino, F.; Gallo, O.; Lanza, P.; Quattrone, A. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov. Disord.,  2011, 26(3), 527-533.
 [http://dx.doi.org/10.1002/mds.23529] [PMID: 21287599]

[66]
Constantinides, V.C.; Paraskevas, G.P.; Velonakis, G.; Toulas, P.; Stamboulis, E.; Kapaki, E. MRI planimetry and magnetic resonance parkinsonism index in the differential diagnosis of patients with parkinsonism. AJNR Am. J. Neuroradiol.,  2018, 39(6), 1047-1051.
 [http://dx.doi.org/10.3174/ajnr.A5618] [PMID: 29622555]

[67]
Archer, D.B.; Mitchell, T.; Burciu, R.G.; Yang, J.; Nigro, S.; Quattrone, A.; Quattrone, A.; Jeromin, A.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Magnetic resonance imaging and neurofilament light in the differentiation of parkinsonism. Mov. Disord.,  2020, 35(8), 1388-1395.
 [http://dx.doi.org/10.1002/mds.28060] [PMID: 32357259]

[68]
Quattrone, A.; Antonini, A.; Vaillancourt, D.E.; Seppi, K.; Ceravolo, R.; Strafella, A.P.; Morelli, M.; Nigro, S.; Vescio, B.; Bianco, M.G.; Vasta, R.; Arcuri, P.P.; Weis, L.; Fiorenzato, E.; Biundo, R.; Burciu, R.G.; Krismer, F.; McFarland, N.R.; Mueller, C.; Gizewski, E.R.; Cosottini, M.; Del Prete, E.; Mazzucchi, S.; Quattrone, A. A New MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson’s Disease in clinical practice: An international study. Mov. Disord.,  2021, 36(3), 681-689.
 [http://dx.doi.org/10.1002/mds.28364] [PMID: 33151015]

[69]
Quattrone, A.; Morelli, M.; Nigro, S.; Quattrone, A.; Vescio, B.; Arabia, G.; Nicoletti, G.; Nisticò, R.; Salsone, M.; Novellino, F.; Barbagallo, G.; Le Piane, E.; Pugliese, P.; Bosco, D.; Vaccaro, M.G.; Chiriaco, C.; Sabatini, U.; Vescio, V.; Stanà, C.; Rocca, F.; Gullà, D.; Caracciolo, M. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson’s disease. Parkinsonism Relat. Disord.,  2018, 54, 3-8.
 [http://dx.doi.org/10.1016/j.parkreldis.2018.07.016] [PMID: 30068492]

[70]
Quattrone, A.; Morelli, M.; Vescio, B.; Nigro, S.; Le Piane, E.; Sabatini, U.; Caracciolo, M.; Vescio, V.; Quattrone, A.; Barbagallo, G.; Stanà, C.; Nicoletti, G.; Arabia, G.; Nisticò, R.; Novellino, F.; Salsone, M. Refining initial diagnosis of Parkinson’s disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study. Mov. Disord.,  2019, 34(4), 487-495.
 [http://dx.doi.org/10.1002/mds.27621] [PMID: 30759325]

[71]
Chougar, L.; Faouzi, J.; Pyatigorskaya, N.; Yahia-Cherif, L.; Gaurav, R.; Biondetti, E.; Villotte, M.; Valabrègue, R.; Corvol, J.C.; Brice, A.; Mariani, L.L.; Cormier, F.; Vidailhet, M.; Dupont, G.; Piot, I.; Grabli, D.; Payan, C.; Colliot, O.; Degos, B.; Lehéricy, S. Automated categorization of parkinsonian syndromes using magnetic resonance imaging in a clinical setting. Mov. Disord.,  2021, 36(2), 460-470.
 [http://dx.doi.org/10.1002/mds.28348] [PMID: 33137232]

[72]
Hofer, S.; Frahm, J. Topography of the human corpus callosum revisited—Comprehensive fiber tractography using diffusion tensor magnetic resonance imaging. Neuroimage,  2006, 32(3), 989-994.
 [http://dx.doi.org/10.1016/j.neuroimage.2006.05.044] [PMID: 16854598]

[73]
Pasternak, O.; Sochen, N.; Gur, Y.; Intrator, N.; Assaf, Y. Free water elimination and mapping from diffusion MRI. Magn. Reson. Med.,  2009, 62(3), 717-730.
 [http://dx.doi.org/10.1002/mrm.22055] [PMID: 19623619]

[74]
Mitchell, T.; Archer, D.B.; Chu, W.T.; Coombes, S.A.; Lai, S.; Wilkes, B.J.; McFarland, N.R.; Okun, M.S.; Black, M.L.; Herschel, E.; Simuni, T.; Comella, C.; Xie, T.; Li, H.; Parrish, T.B.; Kurani, A.S.; Corcos, D.M.; Vaillancourt, D.E. Neurite orientation dispersion and density imaging (NODDI) and free‐water imaging in Parkinsonism. Hum. Brain Mapp.,  2019, 40(17), 5094-5107.
 [http://dx.doi.org/10.1002/hbm.24760] [PMID: 31403737]

[75]
Wang, Y.; Wang, Q.; Haldar, J.P.; Yeh, F.C.; Xie, M.; Sun, P.; Tu, T.W.; Trinkaus, K.; Klein, R.S.; Cross, A.H.; Song, S.K. Quantification of increased cellularity during inflammatory demyelination. Brain,  2011, 134(12), 3590-3601.
 [http://dx.doi.org/10.1093/brain/awr307] [PMID: 22171354]

[76]
Febo, M.; Perez, P.D.; Ceballos-Diaz, C.; Colon-Perez, L.M.; Zeng, H.; Ofori, E.; Golde, T.E.; Vaillancourt, D.E.; Chakrabarty, P. Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-γ. Brain Struct. Funct.,  2020, 225(1), 427-439.
 [http://dx.doi.org/10.1007/s00429-019-02017-1] [PMID: 31894407]

[77]
Planetta, P.J.; Ofori, E.; Pasternak, O.; Burciu, R.G.; Shukla, P.; DeSimone, J.C.; Okun, M.S.; McFarland, N.R.; Vaillancourt, D.E. Free-water imaging in Parkinson’s disease and atypical parkinsonism. Brain,  2016, 139(2), 495-508.
 [http://dx.doi.org/10.1093/brain/awv361] [PMID: 26705348]

[78]
Archer, D.B.; Bricker, J.T.; Chu, W.T.; Burciu, R.G.; McCracken, J.L.; Lai, S.; Coombes, S.A.; Fang, R.; Barmpoutis, A.; Corcos, D.M.; Kurani, A.S.; Mitchell, T.; Black, M.L.; Herschel, E.; Simuni, T.; Parrish, T.B.; Comella, C.; Xie, T.; Seppi, K.; Bohnen, N.I.; Müller, M.L.T.M.; Albin, R.L.; Krismer, F.; Du, G.; Lewis, M.M.; Huang, X.; Li, H.; Pasternak, O.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): A multicentre machine learning study. Lancet Digit. Health,  2019, 1(5), e222-e231.
 [http://dx.doi.org/10.1016/S2589-7500(19)30105-0] [PMID: 32259098]

[79]
Burciu, R.G.; Ofori, E.; Archer, D.B.; Wu, S.S.; Pasternak, O.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Progression marker of Parkinson’s disease: A 4-year multi-site imaging study. Brain,  2017, 140(8), 2183-2192.
 [http://dx.doi.org/10.1093/brain/awx146] [PMID: 28899020]

[80]
Guttuso, T., Jr; Bergsland, N.; Hagemeier, J.; Lichter, D.G.; Pasternak, O.; Zivadinov, R. Substantia nigra free water increases longitudinally in Parkinson Disease. AJNR Am. J. Neuroradiol.,  2018, 39(3), 479-484.
 [http://dx.doi.org/10.3174/ajnr.A5545] [PMID: 29419398]

[81]
Ofori, E.; Krismer, F.; Burciu, R.G.; Pasternak, O.; McCracken, J.L.; Lewis, M.M.; Du, G.; McFarland, N.R.; Okun, M.S.; Poewe, W.; Mueller, C.; Gizewski, E.R.; Schocke, M.; Kremser, C.; Li, H.; Huang, X.; Seppi, K.; Vaillancourt, D.E. Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. Mov. Disord.,  2017, 32(10), 1457-1464.
 [http://dx.doi.org/10.1002/mds.27100] [PMID: 28714593]

[82]
Ofori, E.; Pasternak, O.; Planetta, P.J.; Burciu, R.; Snyder, A.; Febo, M.; Golde, T.E.; Okun, M.S.; Vaillancourt, D.E. Increased free water in the substantia nigra of Parkinson’s disease: A single-site and multi-site study. Neurobiol. Aging,  2015, 36(2), 1097-1104.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2014.10.029] [PMID: 25467638]

[83]
Ofori, E.; Pasternak, O.; Planetta, P.J.; Li, H.; Burciu, R.G.; Snyder, A.F.; Lai, S.; Okun, M.S.; Vaillancourt, D.E. Longitudinal changes in free-water within the substantia nigra of Parkinson’s disease. Brain,  2015, 138(8), 2322-2331.
 [http://dx.doi.org/10.1093/brain/awv136] [PMID: 25981960]

[84]
Yang, J.; Archer, D.B.; Burciu, R.G.; Müller, M.L.T.M.; Roy, A.; Ofori, E.; Bohnen, N.I.; Albin, R.L.; Vaillancourt, D.E. Multimodal dopaminergic and free-water imaging in Parkinson’s disease. Parkinsonism Relat. Disord.,  2019, 62, 10-15.
 [http://dx.doi.org/10.1016/j.parkreldis.2019.01.007] [PMID: 30639168]

[85]
Zhou, L.; Li, G.; Zhang, Y.; Zhang, M.; Chen, Z.; Zhang, L.; Wang, X.; Zhang, M.; Ye, G.; Li, Y.; Chen, S.; Li, B.; Wei, H.; Liu, J. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain,  2021, 144(5), 1488-1497.
 [http://dx.doi.org/10.1093/brain/awab039] [PMID: 33880500]

[86]
Mitchell, T.; Wilkes, B.J.; Archer, D.B.; Chu, W.T.; Coombes, S.A.; Lai, S.; McFarland, N.R.; Okun, M.S.; Black, M.L.; Herschel, E.; Simuni, T.; Comella, C.; Afshari, M.; Xie, T.; Li, H.; Parrish, T.B.; Kurani, A.S.; Corcos, D.M.; Vaillancourt, D.E. Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neuroimage Clin.,  2022, 34, 103022.
 [http://dx.doi.org/10.1016/j.nicl.2022.103022] [PMID: 35489192]

[87]
Guttuso, T., Jr; Sirica, D.; Tosun, D.; Zivadinov, R.; Pasternak, O.; Weintraub, D.; Baglio, F.; Bergsland, N. Thalamic dorsomedial nucleus free water correlates with cognitive decline in Parkinson’s Disease. Mov. Disord.,  2022, 37(3), 490-501.
 [http://dx.doi.org/10.1002/mds.28886] [PMID: 34936139]

[88]
Boelmans, K.; Bodammer, N.C.; Suchorska, B.; Kaufmann, J.; Ebersbach, G.; Heinze, H.J.; Niehaus, L. Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease. Parkinsonism Relat. Disord.,  2010, 16(8), 498-502.
 [http://dx.doi.org/10.1016/j.parkreldis.2010.05.006] [PMID: 20573537]

[89]
Erbetta, A.; Mandelli, M.L.; Savoiardo, M.; Grisoli, M.; Bizzi, A.; Soliveri, P.; Chiapparini, L.; Prioni, S.; Bruzzone, M.G.; Girotti, F. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am. J. Neuroradiol.,  2009, 30(8), 1482-1487.
 [http://dx.doi.org/10.3174/ajnr.A1615] [PMID: 19589886]

[90]
Rizzo, G.; Martinelli, P.; Manners, D.; Scaglione, C.; Tonon, C.; Cortelli, P.; Malucelli, E.; Capellari, S.; Testa, C.; Parchi, P.; Montagna, P.; Barbiroli, B.; Lodi, R. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson’s disease. Brain,  2008, 131(10), 2690-2700.
 [http://dx.doi.org/10.1093/brain/awn195] [PMID: 18819991]

[91]
Whitwell, J.L.; Schwarz, C.G.; Reid, R.I.; Kantarci, K.; Jack, C.R., Jr; Josephs, K.A. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat. Disord.,  2014, 20(5), 493-498.
 [http://dx.doi.org/10.1016/j.parkreldis.2014.01.023] [PMID: 24656943]

[92]
Boelmans, K.; Kaufmann, J.; Bodammer, N.; Ebersbach, G.; Behlau, G.; Heinze, H.J.; Niehaus, L. Involvement of motor pathways in corticobasal syndrome detected by diffusion tensor tractography. Mov. Disord.,  2009, 24(2), 168-175.
 [http://dx.doi.org/10.1002/mds.22193] [PMID: 18973249]

[93]
Gore, J.C. Principles and practice of functional MRI of the human brain. J. Clin. Invest.,  2003, 112(1), 4-9.
 [http://dx.doi.org/10.1172/JCI200319010] [PMID: 12840051]

[94]
Baggio, H.C.; Abos, A.; Segura, B.; Campabadal, A.; Uribe, C.; Giraldo, D.M.; Perez-Soriano, A.; Muñoz, E.; Compta, Y.; Junque, C.; Marti, M.J. Cerebellar resting-state functional connectivity in Parkinson’s disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. Neuroimage Clin.,  2019, 22, 101720.
 [http://dx.doi.org/10.1016/j.nicl.2019.101720] [PMID: 30785051]

[95]
Ballarini, T.; Albrecht, F.; Mueller, K.; Jech, R.; Diehl-Schmid, J.; Fliessbach, K.; Kassubek, J.; Lauer, M.; Fassbender, K.; Schneider, A.; Synofzik, M.; Wiltfang, J.; Otto, M.; Schroeter, M.L. Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. Neuroimage Clin.,  2020, 25, 102112.
 [http://dx.doi.org/10.1016/j.nicl.2019.102112] [PMID: 31821953]

[96]
Brown, J.A.; Hua, A.Y.; Trujillo, A.; Attygalle, S.; Binney, R.J.; Spina, S.; Lee, S.E.; Kramer, J.H.; Miller, B.L.; Rosen, H.J.; Boxer, A.L.; Seeley, W.W. Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. Neuroimage Clin.,  2017, 16, 564-574.
 [http://dx.doi.org/10.1016/j.nicl.2017.09.008] [PMID: 28951832]

[97]
Bharti, K.; Bologna, M.; Upadhyay, N.; Piattella, M.C.; Suppa, A.; Petsas, N.; Giannì, C.; Tona, F.; Berardelli, A.; Pantano, P. Abnormal resting-state functional connectivity in progressive supranuclear palsy and corticobasal syndrome. Front. Neurol.,  2017, 8, 248.
 [http://dx.doi.org/10.3389/fneur.2017.00248] [PMID: 28634465]

[98]
Upadhyay, N.; Suppa, A.; Piattella, M.C.; Giannì, C.; Bologna, M.; Di Stasio, F.; Petsas, N.; Tona, F.; Fabbrini, G.; Berardelli, A.; Pantano, P. Functional disconnection of thalamic and cerebellar dentate nucleus networks in progressive supranuclear palsy and corticobasal syndrome. Parkinsonism Relat. Disord.,  2017, 39, 52-57.
 [http://dx.doi.org/10.1016/j.parkreldis.2017.03.008] [PMID: 28318985]

[99]
Prodoehl, J.; Burciu, R.G.; Vaillancourt, D.E. Resting state functional magnetic resonance imaging in Parkinson’s disease. Curr. Neurol. Neurosci. Rep.,  2014, 14(6), 448.
 [http://dx.doi.org/10.1007/s11910-014-0448-6] [PMID: 24744021]

[100]
Rosskopf, J.; Gorges, M.; Müller, H.P.; Pinkhardt, E.H.; Ludolph, A.C.; Kassubek, J. Hyperconnective and hypoconnective cortical and subcortical functional networks in multiple system atrophy. Parkinsonism Relat. Disord.,  2018, 49, 75-80.
 [http://dx.doi.org/10.1016/j.parkreldis.2018.01.012] [PMID: 29352721]

[101]
Yao, Q.; Zhu, D.; Li, F.; Xiao, C.; Lin, X.; Huang, Q.; Shi, J. Altered functional and causal connectivity of cerebello-cortical circuits between multiple system atrophy (Parkinsonian Type) and Parkinson’s Disease. Front. Aging Neurosci.,  2017, 9, 266.
 [http://dx.doi.org/10.3389/fnagi.2017.00266] [PMID: 28848423]

[102]
Vo, A.; Sako, W.; Fujita, K.; Peng, S.; Mattis, P.J.; Skidmore, F.M.; Ma, Y.; Uluğ, A.M.; Eidelberg, D. Parkinson’s disease-related network topographies characterized with resting state functional MRI. Hum. Brain Mapp.,  2017, 38(2), 617-630.
 [http://dx.doi.org/10.1002/hbm.23260] [PMID: 27207613]

[103]
Rommal, A.; Vo, A.; Schindlbeck, K.A.; Greuel, A.; Ruppert, M.C.; Eggers, C.; Eidelberg, D. Parkinson’s disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study. Neuroimage. Reports,  2021, 1(3), 100026.
 [http://dx.doi.org/10.1016/j.ynirp.2021.100026]

[104]
Ma, Y.; Tang, C.; Spetsieris, P.G.; Dhawan, V.; Eidelberg, D. Abnormal metabolic network activity in Parkinson’s disease: Test-retest reproducibility. J. Cereb. Blood Flow Metab.,  2007, 27(3), 597-605.
 [http://dx.doi.org/10.1038/sj.jcbfm.9600358] [PMID: 16804550]

[105]
Burciu, R.G.; Chung, J.W.; Shukla, P.; Ofori, E.; Li, H.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. Neurology,  2016, 87(7), 709-717.
 [http://dx.doi.org/10.1212/WNL.0000000000002985] [PMID: 27421545]

[106]
Burciu, R.G.; Ofori, E.; Shukla, P.; Pasternak, O.; Chung, J.W.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Free-water and BOLD imaging changes in Parkinson’s disease patients chronically treated with a MAO-B inhibitor. Hum. Brain Mapp.,  2016, 37(8), 2894-2903.
 [http://dx.doi.org/10.1002/hbm.23213] [PMID: 27089850]

[107]
Planetta, P.J.; Kurani, A.S.; Shukla, P.; Prodoehl, J.; Corcos, D.M.; Comella, C.L.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Distinct functional and macrostructural brain changes in Parkinson’s disease and multiple system atrophy. Hum. Brain Mapp.,  2015, 36(3), 1165-1179.
 [http://dx.doi.org/10.1002/hbm.22694] [PMID: 25413603]

[108]
Eckert, T.; Tang, C.; Ma, Y.; Brown, N.; Lin, T.; Frucht, S.; Feigin, A.; Eidelberg, D. Abnormal metabolic networks in atypical parkinsonism. Mov. Disord.,  2008, 23(5), 727-733.
 [http://dx.doi.org/10.1002/mds.21933] [PMID: 18186116]

[109]
Borogovac, A.; Asllani, I. Arterial Spin Labeling (ASL) fMRI: Advantages, theoretical constrains, and experimental challenges in neurosciences. Int. J. Biomed. Imaging,  2012, 2012, 818456.
 [PMID: 22966219]

[110]
Soldozy, S.; Galindo, J.; Snyder, H.; Ali, Y.; Norat, P.; Yağmurlu, K.; Sokolowski, J.D.; Sharifi, K.; Tvrdik, P.; Park, M.S.; Kalani, M.Y.S. Clinical utility of arterial spin labeling imaging in disorders of the nervous system. Neurosurg. Focus,  2019, 47(6), E5.
 [http://dx.doi.org/10.3171/2019.9.FOCUS19567] [PMID: 31786550]

[111]
Melzer, T.R.; Watts, R.; MacAskill, M.R.; Pearson, J.F.; Rüeger, S.; Pitcher, T.L.; Livingston, L.; Graham, C.; Keenan, R.; Shankaranarayanan, A.; Alsop, D.C.; Dalrymple-Alford, J.C.; Anderson, T.J. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain,  2011, 134(3), 845-855.
 [http://dx.doi.org/10.1093/brain/awq377] [PMID: 21310726]

[112]
Cheng, L.; Wu, X.; Guo, R.; Wang, Y.; Wang, W.; He, P.; Lin, H.; Shen, J. Discriminative pattern of reduced cerebral blood flow in Parkinson’s disease and Parkinsonism-Plus syndrome: an ASL-MRI study. BMC Med. Imaging,  2020, 20(1), 78.
 [http://dx.doi.org/10.1186/s12880-020-00479-y] [PMID: 32660445]

[113]
Cui, B.; Zheng, W.; Ren, S.; Chen, Z.; Wang, Z. Differentiation of cerebellum-type and parkinson-type of multiple system atrophy by using multimodal MRI parameters. Front. Aging Neurosci.,  2021, 13, 687649.
 [http://dx.doi.org/10.3389/fnagi.2021.687649] [PMID: 34413766]

[114]
Erro, R.; Ponticorvo, S.; Manara, R.; Barone, P.; Picillo, M.; Scannapieco, S.; Cicarelli, G.; Squillante, M.; Volpe, G.; Esposito, F.; Pellecchia, M.T. Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. Parkinsonism Relat. Disord.,  2020, 72, 49-55.
 [http://dx.doi.org/10.1016/j.parkreldis.2020.02.009] [PMID: 32109737]

[115]
Zheng, W.; Ren, S.; Zhang, H.; Liu, M.; Zhang, Q.; Chen, Z.; Wang, Z. Spatial patterns of decreased cerebral blood flow and functional connectivity in multiple system atrophy (Cerebellar-Type): A combined arterial spin labeling perfusion and resting state functional magnetic resonance imaging study. Front. Neurosci.,  2019, 13, 777.
 [http://dx.doi.org/10.3389/fnins.2019.00777] [PMID: 31417345]

[116]
Fernández-Seara, M.A.; Mengual, E.; Vidorreta, M.; Aznárez-Sanado, M.; Loayza, F.R.; Villagra, F.; Irigoyen, J.; Pastor, M.A. Cortical hypoperfusion in Parkinson’s disease assessed using arterial spin labeled perfusion MRI. Neuroimage,  2012, 59(3), 2743-2750.
 [http://dx.doi.org/10.1016/j.neuroimage.2011.10.033] [PMID: 22032942]

[117]
Pelizzari, L.; Di Tella, S.; Rossetto, F.; Laganà, M.M.; Bergsland, N.; Pirastru, A.; Meloni, M.; Nemni, R.; Baglio, F. Parietal perfusion alterations in Parkinson’s Disease patients without dementia. Front. Neurol.,  2020, 11, 562.
 [http://dx.doi.org/10.3389/fneur.2020.00562] [PMID: 32655485]

[118]
Liu, Z.; Zhang, Y.; Wang, H.; Xu, D.; You, H.; Zuo, Z.; Feng, F. Altered cerebral perfusion and microstructure in advanced Parkinson’s disease and their associations with clinical features. Neurol. Res.,  2022, 44(1), 47-56.
 [http://dx.doi.org/10.1080/01616412.2021.1954842] [PMID: 34313185]

[119]
Puig, O.; Henriksen, O.M.; Vestergaard, M.B.; Hansen, A.E.; Andersen, F.L.; Ladefoged, C.N.; Rostrup, E.; Larsson, H.B.W.; Lindberg, U.; Law, I. Comparison of simultaneous arterial spin labeling MRI and 15 O-H 2 O PET measurements of regional cerebral blood flow in rest and altered perfusion states. J. Cereb. Blood Flow Metab.,  2020, 40(8), 1621-1633.
 [http://dx.doi.org/10.1177/0271678X19874643] [PMID: 31500521]

[120]
Helmich, R.C. The cerebral basis of Parkinsonian tremor: A network perspective. Mov. Disord.,  2018, 33(2), 219-231.
 [http://dx.doi.org/10.1002/mds.27224] [PMID: 29119634]

[121]
Dirkx, M.F.; den Ouden, H.; Aarts, E.; Timmer, M.; Bloem, B.R.; Toni, I.; Helmich, R.C. The cerebral network of Parkinson’s Tremor: An effective connectivity fMRI study. J. Neurosci.,  2016, 36(19), 5362-5372.
 [http://dx.doi.org/10.1523/JNEUROSCI.3634-15.2016] [PMID: 27170132]

[122]
Helmich, R.C.; Janssen, M.J.R.; Oyen, W.J.G.; Bloem, B.R.; Toni, I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann. Neurol.,  2011, 69(2), 269-281.
 [http://dx.doi.org/10.1002/ana.22361] [PMID: 21387372]

[123]
Fujioka, S.; Algom, A.A.; Murray, M.E.; Sanchez-Contreras, M.Y.; Tacik, P.; Tsuboi, Y.; Van Gerpen, J.A.; Uitti, R.J.; Rademakers, R.; Ross, O.A.; Wszolek, Z.K.; Dickson, D.W. Tremor in progressive supranuclear palsy. Parkinsonism Relat. Disord.,  2016, 27, 93-97.
 [http://dx.doi.org/10.1016/j.parkreldis.2016.03.015] [PMID: 27039056]

[124]
Kaindlstorfer, C.; Granata, R.; Wenning, G.K. Tremor in Multiple System Atrophy-a review. Tremor Other Hyperkinet. Mov. (N.Y.),  2013, 3, 03.
 [http://dx.doi.org/10.5334/tohm.166] [PMID: 24116345]

[125]
Pal, P.K.; Mailankody, P.; Netravathi, M. Review of tremor in Parkinson’s disease and atypical parkinsonian disorders. Neurol. India,  2017, 65(5), 1083-1090.
 [http://dx.doi.org/10.4103/neuroindia.NI_880_16] [PMID: 28879902]

[126]
Su, D.; Yang, S.; Hu, W.; Wang, D.; Kou, W.; Liu, Z.; Wang, X.; Wang, Y.; Ma, H.; Sui, Y.; Zhou, J.; Pan, H.; Feng, T. The characteristics of tremor motion help identify Parkinson’s Disease and multiple system atrophy. Front. Neurol.,  2020, 11, 540.
 [http://dx.doi.org/10.3389/fneur.2020.00540] [PMID: 32754107]

[127]
Berg, D.; Postuma, R.B.; Bloem, B.; Chan, P.; Dubois, B.; Gasser, T.; Goetz, C.G.; Halliday, G.M.; Hardy, J.; Lang, A.E.; Litvan, I.; Marek, K.; Obeso, J.; Oertel, W.; Olanow, C.W.; Poewe, W.; Stern, M.; Deuschl, G. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov. Disord.,  2014, 29(4), 454-462.
 [http://dx.doi.org/10.1002/mds.25844] [PMID: 24619848]

[128]
Mantri, S.; Morley, J.F.; Siderowf, A.D. The importance of preclinical diagnostics in Parkinson disease. Parkinsonism Relat. Disord.,  2019, 64, 20-28.
 [http://dx.doi.org/10.1016/j.parkreldis.2018.09.011] [PMID: 30224266]

[129]
Noyce, A.J.; Lees, A.J.; Schrag, A.E. The prediagnostic phase of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry,  2016, 87(8), 871-878.
 [http://dx.doi.org/10.1136/jnnp-2015-311890] [PMID: 26848171]

[130]
Pellicano, C.; Benincasa, D.; Pisani, V.; Buttarelli, F.R.; Giovannelli, M.; Pontieri, F.E. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr. Dis. Treat.,  2007, 3(1), 145-151.
 [http://dx.doi.org/10.2147/nedt.2007.3.1.145] [PMID: 19300544]

[131]
Postuma, R.B.; Aarsland, D.; Barone, P.; Burn, D.J.; Hawkes, C.H.; Oertel, W.; Ziemssen, T. Identifying prodromal Parkinson’s disease: Pre-Motor disorders in Parkinson’s disease. Mov. Disord.,  2012, 27(5), 617-626.
 [http://dx.doi.org/10.1002/mds.24996] [PMID: 22508280]

[132]
Greffard, S.; Verny, M.; Bonnet, A.M.; Beinis, J.Y.; Gallinari, C.; Meaume, S.; Piette, F.; Hauw, J.J.; Duyckaerts, C. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol.,  2006, 63(4), 584-588.
 [http://dx.doi.org/10.1001/archneur.63.4.584] [PMID: 16606773]

[133]
Barber, T.R.; Klein, J.C.; Mackay, C.E.; Hu, M.T.M. Neuroimaging in pre-motor Parkinson’s disease. Neuroimage Clin.,  2017, 15, 215-227.
 [http://dx.doi.org/10.1016/j.nicl.2017.04.011] [PMID: 28529878]

[134]
Klein, C.; Westenberger, A. Genetics of Parkinson’s disease. Cold Spring Harb. Perspect. Med.,  2012, 2(1), a008888.
 [http://dx.doi.org/10.1101/cshperspect.a008888] [PMID: 22315721]

[135]
Healy, D.G.; Falchi, M.; O’Sullivan, S.S.; Bonifati, V.; Durr, A.; Bressman, S.; Brice, A.; Aasly, J.; Zabetian, C.P.; Goldwurm, S.; Ferreira, J.J.; Tolosa, E.; Kay, D.M.; Klein, C.; Williams, D.R.; Marras, C.; Lang, A.E.; Wszolek, Z.K.; Berciano, J.; Schapira, A.H.V.; Lynch, T.; Bhatia, K.P.; Gasser, T.; Lees, A.J.; Wood, N.W.; International, L.C. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol.,  2008, 7(7), 583-590.
 [http://dx.doi.org/10.1016/S1474-4422(08)70117-0] [PMID: 18539534]

[136]
Marder, K.; Wang, Y.; Alcalay, R.N.; Mejia-Santana, H.; Tang, M.X.; Lee, A.; Raymond, D.; Mirelman, A.; Saunders-Pullman, R.; Clark, L.; Ozelius, L.; Orr-Urtreger, A.; Giladi, N.; Bressman, S.; Consortium, L.A.J. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology,  2015, 85(1), 89-95.
 [http://dx.doi.org/10.1212/WNL.0000000000001708] [PMID: 26062626]

[137]
Sierra, M.; González-Aramburu, I.; Sánchez-Juan, P.; Sánchez-Quintana, C.; Polo, J.M.; Berciano, J.; Combarros, O.; Infante, J. High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson’s disease patients in Cantabria (Spain). Mov. Disord.,  2011, 26(13), 2343-2346.
 [http://dx.doi.org/10.1002/mds.23965] [PMID: 21954089]

[138]
Heinzel, S.; Berg, D.; Gasser, T.; Chen, H.; Yao, C.; Postuma, R.B. MDS Task Force on the Definition of Parkinson’s Disease. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov. Disord.,  2019, 34(10), 1464-1470.
 [http://dx.doi.org/10.1002/mds.27802] [PMID: 31412427]

[139]
Hu, M.T. REM sleep behavior disorder (RBD). Neurobiol. Dis.,  2020, 143, 104996.
 [http://dx.doi.org/10.1016/j.nbd.2020.104996] [PMID: 32599063]

[140]
Galbiati, A.; Verga, L.; Giora, E.; Zucconi, M.; Ferini-Strambi, L. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med. Rev.,  2019, 43, 37-46.
 [http://dx.doi.org/10.1016/j.smrv.2018.09.008] [PMID: 30503716]

[141]
Postuma, R.B.; Iranzo, A.; Hu, M.; Högl, B.; Boeve, B.F.; Manni, R.; Oertel, W.H.; Arnulf, I.; Ferini-Strambi, L.; Puligheddu, M.; Antelmi, E.; Cochen De Cock, V.; Arnaldi, D.; Mollenhauer, B.; Videnovic, A.; Sonka, K.; Jung, K.Y.; Kunz, D.; Dauvilliers, Y.; Provini, F.; Lewis, S.J.; Buskova, J.; Pavlova, M.; Heidbreder, A.; Montplaisir, J.Y.; Santamaria, J.; Barber, T.R.; Stefani, A.; St Louis, E.K.; Terzaghi, M.; Janzen, A.; Leu-Semenescu, S.; Plazzi, G.; Nobili, F.; Sixel-Doering, F.; Dusek, P.; Bes, F.; Cortelli, P.; Ehgoetz Martens, K.; Gagnon, J.F.; Gaig, C.; Zucconi, M.; Trenkwalder, C.; Gan-Or, Z.; Lo, C.; Rolinski, M.; Mahlknecht, P.; Holzknecht, E.; Boeve, A.R.; Teigen, L.N.; Toscano, G.; Mayer, G.; Morbelli, S.; Dawson, B.; Pelletier, A. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study. Brain,  2019, 142(3), 744-759.
 [http://dx.doi.org/10.1093/brain/awz030] [PMID: 30789229]

[142]
Boeve, B.F.; Silber, M.H.; Ferman, T.J.; Lin, S.C.; Benarroch, E.E.; Schmeichel, A.M.; Ahlskog, J.E.; Caselli, R.J.; Jacobson, S.; Sabbagh, M.; Adler, C.; Woodruff, B.; Beach, T.G.; Iranzo, A.; Gelpi, E.; Santamaria, J.; Tolosa, E.; Singer, C.; Mash, D.C.; Luca, C.; Arnulf, I.; Duyckaerts, C.; Schenck, C.H.; Mahowald, M.W.; Dauvilliers, Y.; Graff-Radford, N.R.; Wszolek, Z.K.; Parisi, J.E.; Dugger, B.; Murray, M.E.; Dickson, D.W. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med.,  2013, 14(8), 754-762.
 [http://dx.doi.org/10.1016/j.sleep.2012.10.015] [PMID: 23474058]

[143]
Arnaldi, D.; Chincarini, A.; Hu, M.T.; Sonka, K.; Boeve, B.; Miyamoto, T.; Puligheddu, M.; De Cock, V.C.; Terzaghi, M.; Plazzi, G.; Tachibana, N.; Morbelli, S.; Rolinski, M.; Dusek, P.; Lowe, V.; Miyamoto, M.; Figorilli, M.; Verbizier, D.; Bossert, I.; Antelmi, E.; Meli, R.; Barber, T.R.; Trnka, J.; Miyagawa, T.; Serra, A.; Pizza, F.; Bauckneht, M.; Bradley, K.M.; Zogala, D.; McGowan, D.R.; Jordan, L.; Manni, R.; Nobili, F. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain,  2021, 144(1), 278-287.
 [http://dx.doi.org/10.1093/brain/awaa365] [PMID: 33348363]

[144]
Iranzo, A.; Santamaría, J.; Valldeoriola, F.; Serradell, M.; Salamero, M.; Gaig, C.; Niñerola-Baizán, A.; Sánchez-Valle, R.; Lladó, A.; De Marzi, R.; Stefani, A.; Seppi, K.; Pavia, J.; Högl, B.; Poewe, W.; Tolosa, E.; Lomeña, F. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol.,  2017, 82(3), 419-428.
 [http://dx.doi.org/10.1002/ana.25026] [PMID: 28833467]

[145]
Iranzo, A.; Stefani, A.; Niñerola-Baizan, A.; Stokner, H.; Serradell, M.; Vilas, D.; Holzknecht, E.; Gaig, C.; Pavia, J.; Lomeña, F.; Reyes, D.; Seppi, K.; Santamaria, J.; Högl, B.; Tolosa, E.; Poewe, W. Sleep Innsbruck Barcelona (SINBAR) Group. Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder. Neurology,  2020, 94(15), e1605-e1613.
 [http://dx.doi.org/10.1212/WNL.0000000000009246] [PMID: 32161031]

[146]
Iranzo, A.; Valldeoriola, F.; Lomeña, F.; Molinuevo, J.L.; Serradell, M.; Salamero, M.; Cot, A.; Ros, D.; Pavía, J.; Santamaria, J.; Tolosa, E. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. Lancet Neurol.,  2011, 10(9), 797-805.
 [http://dx.doi.org/10.1016/S1474-4422(11)70152-1] [PMID: 21802993]

[147]
Iranzo, A.; Lomeña, F.; Stockner, H.; Valldeoriola, F.; Vilaseca, I.; Salamero, M.; Molinuevo, J.L.; Serradell, M.; Duch, J.; Pavía, J.; Gallego, J.; Seppi, K.; Högl, B.; Tolosa, E.; Poewe, W.; Santamaria, J. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. Lancet Neurol.,  2010, 9(11), 1070-1077.
 [http://dx.doi.org/10.1016/S1474-4422(10)70216-7] [PMID: 20846908]

[148]
Arnaldi, D.; De Carli, F.; Picco, A.; Ferrara, M.; Accardo, J.; Bossert, I.; Famà, F.; Girtler, N.; Morbelli, S.; Sambuceti, G.; Nobili, F. Nigro-caudate dopaminergic deafferentation: A marker of REM sleep behavior disorder? Neurobiol. Aging,  2015, 36(12), 3300-3305.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2015.08.025] [PMID: 26410306]

[149]
Eisensehr, I.; Linke, R.; Noachtar, S.; Schwarz, J.; Gildehaus, F.J.; Tatsch, K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Brain,  2000, 123(6), 1155-1160.
 [http://dx.doi.org/10.1093/brain/123.6.1155] [PMID: 10825354]

[150]
Li, Y.; Kang, W.; Yang, Q.; Zhang, L.; Zhang, L.; Dong, F.; Chen, S.; Liu, J. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology,  2017, 88(16), 1493-1500.
 [http://dx.doi.org/10.1212/WNL.0000000000003838] [PMID: 28330956]

[151]
Meles, S.K.; Vadasz, D.; Renken, R.J.; Sittig-Wiegand, E.; Mayer, G.; Depboylu, C.; Reetz, K.; Overeem, S.; Pijpers, A.; Reesink, F.E.; van Laar, T.; Heinen, L.; Teune, L.K.; Höffken, H.; Luster, M.; Kesper, K.; Adriaanse, S.M.; Booij, J.; Leenders, K.L.; Oertel, W.H. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Mov. Disord.,  2017, 32(10), 1482-1486.
 [http://dx.doi.org/10.1002/mds.27094] [PMID: 28734065]

[152]
Bae, Y.J.; Kim, J.M.; Kim, K.J.; Kim, E.; Park, H.S.; Kang, S.Y.; Yoon, I.Y.; Lee, J.Y.; Jeon, B.; Kim, S.E. Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: Comparison with 123 I-FP-CIT SPECT. Radiology,  2018, 287(1), 285-293.
 [http://dx.doi.org/10.1148/radiol.2017162486] [PMID: 29232183]

[153]
Yamada, G.; Ueki, Y.; Oishi, N.; Oguri, T.; Fukui, A.; Nakayama, M.; Sano, Y.; Kandori, A.; Kan, H.; Arai, N.; Sakurai, K.; Wada, I.; Matsukawa, N. Nigrostriatal dopaminergic dysfunction and altered functional connectivity in REM Sleep Behavior disorder with mild motor impairment. Front. Neurol.,  2019, 10, 802.
 [http://dx.doi.org/10.3389/fneur.2019.00802] [PMID: 31404164]

[154]
Shin, J.H.; Lee, J.Y.; Kim, Y.K.; Shin, S.A.; Kim, H.; Nam, H.; Jeon, B. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology,  2020, 95(23), e3081-e3092.
 [http://dx.doi.org/10.1212/WNL.0000000000010942] [PMID: 32989104]

[155]
Stokholm, M.G.; Iranzo, A.; Østergaard, K.; Serradell, M.; Otto, M.; Svendsen, K.B.; Garrido, A.; Vilas, D.; Borghammer, P.; Santamaria, J.; Møller, A.; Gaig, C.; Brooks, D.J.; Tolosa, E.; Pavese, N. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol.,  2017, 16(10), 789-796.
 [http://dx.doi.org/10.1016/S1474-4422(17)30173-4] [PMID: 28684245]

[156]
Albin, R.L.; Koeppe, R.A.; Chervin, R.D.; Consens, F.B.; Wernette, K.; Frey, K.A.; Aldrich, M.S. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology,  2000, 55(9), 1410-1412.
 [http://dx.doi.org/10.1212/WNL.55.9.1410] [PMID: 11087796]

[157]
Knudsen, K.; Fedorova, T.D.; Hansen, A.K.; Sommerauer, M.; Otto, M.; Svendsen, K.B.; Nahimi, A.; Stokholm, M.G.; Pavese, N.; Beier, C.P.; Brooks, D.J.; Borghammer, P. In-vivo staging of pathology in REM sleep behaviour disorder: A multimodality imaging case-control study. Lancet Neurol.,  2018, 17(7), 618-628.
 [http://dx.doi.org/10.1016/S1474-4422(18)30162-5] [PMID: 29866443]

[158]
Biondetti, E.; Santin, M.D.; Valabrègue, R.; Mangone, G.; Gaurav, R.; Pyatigorskaya, N.; Hutchison, M.; Yahia-Cherif, L.; Villain, N.; Habert, M.O.; Arnulf, I.; Leu-Semenescu, S.; Dodet, P.; Vila, M.; Corvol, J.C.; Vidailhet, M.; Lehéricy, S. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease. Brain,  2021, 144(10), 3114-3125.
 [http://dx.doi.org/10.1093/brain/awab191] [PMID: 33978742]

[159]
Holtbernd, F.; Gagnon, J.F.; Postuma, R.B.; Ma, Y.; Tang, C.C.; Feigin, A.; Dhawan, V.; Vendette, M.; Soucy, J.P.; Eidelberg, D.; Montplaisir, J. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology,  2014, 82(7), 620-627.
 [http://dx.doi.org/10.1212/WNL.0000000000000130] [PMID: 24453082]

[160]
Shin, J.H.; Lee, J.Y.; Kim, Y.K.; Yoon, E.J.; Kim, H.; Nam, H.; Jeon, B. Parkinson disease-related brain metabolic patterns and neurodegeneration in Isolated REM Sleep behavior disorder. Neurology,  2021, 97(4), e378-e388.
 [http://dx.doi.org/10.1212/WNL.0000000000012228] [PMID: 34011571]

[161]
Wu, P.; Yu, H.; Peng, S.; Dauvilliers, Y.; Wang, J.; Ge, J.; Zhang, H.; Eidelberg, D.; Ma, Y.; Zuo, C. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain,  2014, 137(12), 3122-3128.
 [http://dx.doi.org/10.1093/brain/awu290] [PMID: 25338949]

[162]
Kogan, R.V.; Janzen, A.; Meles, S.K.; Sittig, E.; Renken, R.J.; Gurvits, V.; Mayer, G.; Leenders, K.L.; Oertel, W.H.; Booij, J.; Reetz, K.; Overeem, S.; Pijpers, A.; Bernhard, F.; García, D.V.; Peretti, D.E.; Teune, L.K.; Reesink, F.E.; Kok, J.G. Four‐year follow‐up of [18F]Fluorodeoxyglucose positron emission tomography–based Parkinson’s disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression. Mov. Disord.,  2021, 36(1), 230-235.
 [http://dx.doi.org/10.1002/mds.28260] [PMID: 32909650]

[163]
Hanyu, H.; Inoue, Y.; Sakurai, H.; Kanetaka, H.; Nakamura, M.; Miyamoto, T.; Sasai, T.; Iwamoto, T. Regional cerebral blood flow changes in patients with idiopathic REM sleep behavior disorder. Eur. J. Neurol.,  2011, 18(5), 784-788.
 [http://dx.doi.org/10.1111/j.1468-1331.2010.03283.x] [PMID: 21143707]

[164]
Mazza, S.; Soucy, J.P.; Gravel, P.; Michaud, M.; Postuma, R.; Massicotte-Marquez, J.; Decary, A.; Montplaisir, J. Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology,  2006, 67(9), 1618-1622.
 [http://dx.doi.org/10.1212/01.wnl.0000242879.39415.49] [PMID: 17101893]

[165]
Sakurai, H.; Hanyu, H.; Inoue, Y.; Kanetaka, H.; Nakamura, M.; Miyamoto, T.; Sasai, T.; Iwamoto, T. Longitudinal study of regional cerebral blood flow in elderly patients with idiopathic rapid eye movement sleep behavior disorder. Geriatr. Gerontol. Int.,  2014, 14(1), 115-120.
 [http://dx.doi.org/10.1111/ggi.12068] [PMID: 23586530]

[166]
Shirakawa, S.I.; Takeuchi, N.; Uchimura, N.; Ohyama, T.; Maeda, H.; Abe, T.; Ishibashi, M.; Ohshima, Y.; Ohshima, H. Study of image findings in rapid eye movement sleep behavioural disorder. Psychiatry Clin. Neurosci.,  2002, 56(3), 291-292.
 [http://dx.doi.org/10.1046/j.1440-1819.2002.00961.x] [PMID: 12047600]

[167]
Vendette, M.; Gagnon, J.F.; Soucy, J.P.; Gosselin, N.; Postuma, R.B.; Tuineag, M.; Godin, I.; Montplaisir, J. Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. Mov. Disord.,  2011, 26(9), 1717-1724.
 [http://dx.doi.org/10.1002/mds.23721] [PMID: 21542022]

[168]
Vendette, M.; Montplaisir, J.; Gosselin, N.; Soucy, J.P.; Postuma, R.B.; Dang-Vu, T.T.; Gagnon, J.F. Brain perfusion anomalies in rapid eye movement sleep behavior disorder with mild cognitive impairment. Mov. Disord.,  2012, 27(10), 1255-1261.
 [http://dx.doi.org/10.1002/mds.25034] [PMID: 22791632]

[169]
Dang-Vu, T.T.; Gagnon, J.F.; Vendette, M.; Soucy, J.P.; Postuma, R.B.; Montplaisir, J. Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder. Neurology,  2012, 79(24), 2302-2306.
 [http://dx.doi.org/10.1212/WNL.0b013e318278b658] [PMID: 23115214]

[170]
Ward, R.J.; Zucca, F.A.; Duyn, J.H.; Crichton, R.R.; Zecca, L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol.,  2014, 13(10), 1045-1060.
 [http://dx.doi.org/10.1016/S1474-4422(14)70117-6] [PMID: 25231526]

[171]
Friedman, A.; Galazka-Friedman, J. The history of the research of iron in parkinsonian substantia nigra. J. Neural Transm.,  2012, 119(12), 1507-1510.
 [http://dx.doi.org/10.1007/s00702-012-0894-8] [PMID: 22941506]

[172]
Duyn, J.H.; Schenck, J. Contributions to magnetic susceptibility of brain tissue. NMR Biomed.,  2017, 30(4), e3546.
 [http://dx.doi.org/10.1002/nbm.3546] [PMID: 27240118]

[173]
Ruetten, P.P.R.; Gillard, J.H.; Graves, M.J. Introduction to quantitative susceptibility mapping and susceptibility weighted imaging. Br. J. Radiol.,  2019, 92(1101), 20181016.
 [http://dx.doi.org/10.1259/bjr.20181016] [PMID: 30933548]

[174]
Yan, F.; He, N.; Lin, H.; Li, R. Iron deposition quantification: Applications in the brain and liver. J. Magn. Reson. Imaging,  2018, 48(2), 301-317.
 [http://dx.doi.org/10.1002/jmri.26161] [PMID: 29897645]

[175]
Langkammer, C.; Krebs, N.; Goessler, W.; Scheurer, E.; Ebner, F.; Yen, K.; Fazekas, F.; Ropele, S. Quantitative MR imaging of brain iron: A postmortem validation study. Radiology,  2010, 257(2), 455-462.
 [http://dx.doi.org/10.1148/radiol.10100495] [PMID: 20843991]

[176]
Sun, H.; Walsh, A.J.; Lebel, R.M.; Blevins, G.; Catz, I.; Lu, J.Q.; Johnson, E.S.; Emery, D.J.; Warren, K.G.; Wilman, A.H. Validation of quantitative susceptibility mapping with Perls’ iron staining for subcortical gray matter. Neuroimage,  2015, 105, 486-492.
 [http://dx.doi.org/10.1016/j.neuroimage.2014.11.010] [PMID: 25462797]

[177]
Wang, C.; Foxley, S.; Ansorge, O.; Bangerter-Christensen, S.; Chiew, M.; Leonte, A.; Menke, R.A.L.; Mollink, J.; Pallebage-Gamarallage, M.; Turner, M.R.; Miller, K.L.; Tendler, B.C. Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. Neuroimage,  2020, 222, 117216.
 [http://dx.doi.org/10.1016/j.neuroimage.2020.117216] [PMID: 32745677]

[178]
Pyatigorskaya, N.; Sanz-Morère, C.B.; Gaurav, R.; Biondetti, E.; Valabregue, R.; Santin, M.; Yahia-Cherif, L.; Lehéricy, S. Iron imaging as a diagnostic tool for Parkinson’s disease: A systematic review and meta-analysis. Front. Neurol.,  2020, 11, 366.
 [http://dx.doi.org/10.3389/fneur.2020.00366] [PMID: 32547468]

[179]
Lee, J.H.; Lee, M.S. Brain Iron Accumulation in Atypical Parkinsonian Syndromes: In vivo MRI Evidences for Distinctive Patterns. Front. Neurol.,  2019, 10, 74.
 [http://dx.doi.org/10.3389/fneur.2019.00074] [PMID: 30809185]

[180]
De Marzi, R.; Seppi, K.; Högl, B.; Müller, C.; Scherfler, C.; Stefani, A.; Iranzo, A.; Tolosa, E.; Santamarìa, J.; Gizewski, E.; Schocke, M.; Skalla, E.; Kremser, C.; Poewe, W. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol.,  2016, 79(6), 1026-1030.
 [http://dx.doi.org/10.1002/ana.24646] [PMID: 27016314]

[181]
Sun, J.; Lai, Z.; Ma, J.; Gao, L.; Chen, M.; Chen, J.; Fang, J.; Fan, Y.; Bao, Y.; Zhang, D.; Chan, P.; Yang, Q.; Ye, C.; Wu, T.; Ma, T. Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder. Mov. Disord.,  2020, 35(3), 478-485.
 [http://dx.doi.org/10.1002/mds.27929] [PMID: 31846123]

[182]
Zhang, X.; Chai, C.; Ghassaban, K.; Ye, J.; Huang, Y.; Zhang, T.; Wu, W.; Zhu, J.; Zhang, X.; Haacke, E.M.; Wang, Z.; Xue, R.; Xia, S. Assessing brain iron and volume of subcortical nuclei in idiopathic rapid eye movement sleep behavior disorder. Sleep,  2021, 44(10), zsab131.
 [http://dx.doi.org/10.1093/sleep/zsab131] [PMID: 34015127]

[183]
Lee, J.H.; Han, Y.H.; Cho, J.W.; Lee, J.S.; Lee, S.J.; Kim, D.J.; Kim, T.H.; Kang, B.M.; Kim, T.H.; Mun, C.W. Evaluation of brain iron content in idiopathic REM sleep behavior disorder using quantitative magnetic resonance imaging. Parkinsonism Relat. Disord.,  2014, 20(7), 776-778.
 [http://dx.doi.org/10.1016/j.parkreldis.2014.03.023] [PMID: 24731528]

[184]
Pyatigorskaya, N.; Gaurav, R.; Arnaldi, D.; Leu-Semenescu, S.; Yahia-Cherif, L.; Valabregue, R.; Vidailhet, M.; Arnulf, I.; Lehéricy, S. Magnetic resonance imaging biomarkers to assess substantia nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep,  2017, 40(11)
 [http://dx.doi.org/10.1093/sleep/zsx149] [PMID: 28958075]

[185]
Sulzer, D.; Cassidy, C.; Horga, G.; Kang, U.J.; Fahn, S.; Casella, L.; Pezzoli, G.; Langley, J.; Hu, X.P.; Zucca, F.A.; Isaias, I.U.; Zecca, L. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Parkinsons Dis.,  2018, 4(1), 11.
 [http://dx.doi.org/10.1038/s41531-018-0047-3] [PMID: 29644335]

[186]
Zhang, W.; Phillips, K.; Wielgus, A.R.; Liu, J.; Albertini, A.; Zucca, F.A.; Faust, R.; Qian, S.Y.; Miller, D.S.; Chignell, C.F.; Wilson, B.; Jackson-Lewis, V.; Przedborski, S.; Joset, D.; Loike, J.; Hong, J.S.; Sulzer, D.; Zecca, L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: Implications for progression of Parkinson’s disease. Neurotox. Res.,  2011, 19(1), 63-72.
 [http://dx.doi.org/10.1007/s12640-009-9140-z] [PMID: 19957214]

[187]
Zecca, L.; Fariello, R.; Riederer, P.; Sulzer, D.; Gatti, A.; Tampellini, D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett.,  2002, 510(3), 216-220.
 [http://dx.doi.org/10.1016/S0014-5793(01)03269-0] [PMID: 11801257]

[188]
Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fariello, R.G.; Karatekin, E.; Kleinman, M.H.; Turro, N.; Hornykiewicz, O.; Zucca, F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. USA,  2004, 101(26), 9843-9848.
 [http://dx.doi.org/10.1073/pnas.0403495101] [PMID: 15210960]

[189]
Ohtsuka, C.; Sasaki, M.; Konno, K.; Kato, K.; Takahashi, J.; Yamashita, F.; Terayama, Y. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat. Disord.,  2014, 20(7), 755-760.
 [http://dx.doi.org/10.1016/j.parkreldis.2014.04.005] [PMID: 24768616]

[190]
Biondetti, E.; Gaurav, R.; Yahia-Cherif, L.; Mangone, G.; Pyatigorskaya, N.; Valabrègue, R.; Ewenczyk, C.; Hutchison, M.; François, C.; Arnulf, I.; Corvol, J.C.; Vidailhet, M.; Lehéricy, S. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson’s disease. Brain,  2020, 143(9), 2757-2770.
 [http://dx.doi.org/10.1093/brain/awaa216] [PMID: 32856056]

[191]
Ogisu, K.; Kudo, K.; Sasaki, M.; Sakushima, K.; Yabe, I.; Sasaki, H.; Terae, S.; Nakanishi, M.; Shirato, H. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology,  2013, 55(6), 719-724.
 [http://dx.doi.org/10.1007/s00234-013-1171-8] [PMID: 23525598]

[192]
Ohtsuka, C.; Sasaki, M.; Konno, K.; Koide, M.; Kato, K.; Takahashi, J.; Takahashi, S.; Kudo, K.; Yamashita, F.; Terayama, Y. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci. Lett.,  2013, 541, 93-98.
 [http://dx.doi.org/10.1016/j.neulet.2013.02.012] [PMID: 23428505]

[193]
Pyatigorskaya, N.; Magnin, B.; Mongin, M.; Yahia-Cherif, L.; Valabregue, R.; Arnaldi, D.; Ewenczyk, C.; Poupon, C.; Vidailhet, M.; Lehéricy, S. Comparative STudy of MRI biomarkers in the substantia nigra to discriminate idiopathic Parkinson disease. AJNR Am. J. Neuroradiol.,  2018, 39(8), 1460-1467.
 [http://dx.doi.org/10.3174/ajnr.A5702] [PMID: 29954816]

[194]
Kitao, S.; Matsusue, E.; Fujii, S.; Miyoshi, F.; Kaminou, T.; Kato, S.; Ito, H.; Ogawa, T. Correlation between pathology and neuromelanin MR imaging in Parkinson’s disease and dementia with Lewy bodies. Neuroradiology,  2013, 55(8), 947-953.
 [http://dx.doi.org/10.1007/s00234-013-1199-9] [PMID: 23673875]

[195]
Ehrminger, M.; Latimier, A.; Pyatigorskaya, N.; Garcia-Lorenzo, D.; Leu-Semenescu, S.; Vidailhet, M.; Lehericy, S.; Arnulf, I. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain,  2016, 139(4), 1180-1188.
 [http://dx.doi.org/10.1093/brain/aww006] [PMID: 26920675]

[196]
Luppi, P.H.; Clément, O.; Valencia Garcia, S.; Brischoux, F.; Fort, P. New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: the potential role of glutamate, gamma-aminobutyric acid, and glycine. Sleep Med.,  2013, 14(8), 714-718.
 [http://dx.doi.org/10.1016/j.sleep.2013.02.004] [PMID: 23790501]

[197]
Wang, X.; Zhang, Y.; Zhu, C.; Li, G.; Kang, J.; Chen, F.; Yang, L. The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: Meta-analysis. Neurol. Sci.,  2019, 40(12), 2479-2489.
 [http://dx.doi.org/10.1007/s10072-019-04014-y] [PMID: 31392640]

[198]
Scherfler, C.; Frauscher, B.; Schocke, M.; Iranzo, A.; Gschliesser, V.; Seppi, K.; Santamaria, J.; Tolosa, E.; Högl, B.; Poewe, W.; Group, S. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study. Ann. Neurol.,  2011, 69(2), 400-407.
 [http://dx.doi.org/10.1002/ana.22245] [PMID: 21387382]

[199]
Unger, M.M.; Belke, M.; Menzler, K.; Heverhagen, J.T.; Keil, B.; Stiasny-Kolster, K.; Rosenow, F.; Diederich, N.J.; Mayer, G.; Möller, J.C.; Oertel, W.H.; Knake, S. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep,  2010, 33(6), 767-773.
 [http://dx.doi.org/10.1093/sleep/33.6.767] [PMID: 20550017]

[200]
Holtbernd, F.; Romanzetti, S.; Oertel, W.H.; Knake, S.; Sittig, E.; Heidbreder, A.; Maier, A.; Krahe, J.; Wojtala, J.; Dogan, I.; Schulz, J.B.; Schiefer, J.; Janzen, A.; Reetz, K. Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson’s disease on behalf of the German rapid eye movement sleep behavior disorder study group. Sleep,  2021, 44(3), zsaa199.
 [http://dx.doi.org/10.1093/sleep/zsaa199] [PMID: 32974664]

[201]
Ellmore, T.M.; Hood, A.J.; Castriotta, R.J.; Stimming, E.F.; Bick, R.J.; Schiess, M.C. Reduced volume of the putamen in REM sleep behavior disorder patients. Parkinsonism Relat. Disord.,  2010, 16(10), 645-649.
 [http://dx.doi.org/10.1016/j.parkreldis.2010.08.014] [PMID: 20846895]

[202]
Hanyu, H.; Inoue, Y.; Sakurai, H.; Kanetaka, H.; Nakamura, M.; Miyamoto, T.; Sasai, T.; Iwamoto, T. Voxel-based magnetic resonance imaging study of structural brain changes in patients with idiopathic REM sleep behavior disorder. Parkinsonism Relat. Disord.,  2012, 18(2), 136-139.
 [http://dx.doi.org/10.1016/j.parkreldis.2011.08.023] [PMID: 21924943]

[203]
Rahayel, S.; Montplaisir, J.; Monchi, O.; Bedetti, C.; Postuma, R.B.; Brambati, S.; Carrier, J.; Joubert, S.; Latreille, V.; Jubault, T.; Gagnon, J.F. Patterns of cortical thinning in idiopathic rapid eye movement sleep behavior disorder. Mov. Disord.,  2015, 30(5), 680-687.
 [http://dx.doi.org/10.1002/mds.25820] [PMID: 24676967]

[204]
Rahayel, S.; Postuma, R.B.; Montplaisir, J.; Bedetti, C.; Brambati, S.; Carrier, J.; Monchi, O.; Bourgouin, P.A.; Gaubert, M.; Gagnon, J.F. Abnormal gray matter shape, thickness, and volume in the motor cortico-subcortical loop in idiopathic rapid eye movement sleep behavior disorder: association with clinical and motor features. Cereb. Cortex,  2018, 28(2), 658-671.
 [http://dx.doi.org/10.1093/cercor/bhx137] [PMID: 28591814]

[205]
Rahayel, S.; Postuma, R.B.; Montplaisir, J.; Génier Marchand, D.; Escudier, F.; Gaubert, M.; Bourgouin, P.A.; Carrier, J.; Monchi, O.; Joubert, S.; Blanc, F.; Gagnon, J.F. Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorder. Neurology,  2018, 90(20), e1759-e1770.
 [http://dx.doi.org/10.1212/WNL.0000000000005523] [PMID: 29669906]

[206]
Campabadal, A.; Segura, B.; Junque, C.; Serradell, M.; Abos, A.; Uribe, C.; Baggio, H.C.; Gaig, C.; Santamaria, J.; Compta, Y.; Bargallo, N.; Iranzo, A. Cortical gray matter and hippocampal atrophy in idiopathic rapid eye movement sleep behavior disorder. Front. Neurol.,  2019, 10, 312.
 [http://dx.doi.org/10.3389/fneur.2019.00312] [PMID: 31024418]

[207]
Li, G.; Chen, Z.; Zhou, L.; Zhao, A.; Niu, M.; Li, Y.; Luo, N.; Kang, W.; Liu, J. Altered structure and functional connectivity of the central autonomic network in idiopathic rapid eye movement sleep behaviour disorder. J. Sleep Res.,  2021, 30(3), e13136.
 [http://dx.doi.org/10.1111/jsr.13136] [PMID: 32608031]

[208]
Chen, M.; Li, Y.; Chen, J.; Gao, L.; Sun, J.; Gu, Z.; Wu, T.; Chan, P. Structural and functional brain alterations in patients with idiopathic rapid eye movement sleep behavior disorder. J. Neuroradiol.,  2022, 4(1), 66-72.
 [PMID: 32540338]

[209]
Pereira, J.B.; Weintraub, D.; Chahine, L.; Aarsland, D.; Hansson, O.; Westman, E. Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. NPJ Parkinsons Dis.,  2019, 5(1), 7.
 [http://dx.doi.org/10.1038/s41531-019-0079-3] [PMID: 31069252]

[210]
Campabadal, A.; Inguanzo, A.; Segura, B.; Serradell, M.; Abos, A.; Uribe, C.; Gaig, C.; Santamaria, J.; Compta, Y.; Bargallo, N.; Junque, C.; Iranzo, A. Cortical gray matter progression in idiopathic REM sleep behavior disorder and its relation to cognitive decline. Neuroimage Clin.,  2020, 28, 102421.
 [http://dx.doi.org/10.1016/j.nicl.2020.102421] [PMID: 32957013]

[211]
Campabadal, A.; Abos, A.; Segura, B.; Serradell, M.; Uribe, C.; Baggio, H.C.; Gaig, C.; Santamaria, J.; Compta, Y.; Bargallo, N.; Junque, C.; Iranzo, A. Disruption of posterior brain functional connectivity and its relation to cognitive impairment in idiopathic REM sleep behavior disorder. Neuroimage Clin.,  2020, 25, 102138.
 [http://dx.doi.org/10.1016/j.nicl.2019.102138] [PMID: 31911344]

[212]
Ellmore, T.M.; Castriotta, R.J.; Hendley, K.L.; Aalbers, B.M.; Furr-Stimming, E.; Hood, A.J.; Suescun, J.; Beurlot, M.R.; Hendley, R.T.; Schiess, M.C. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep,  2013, 36(12), 1885-1892.
 [http://dx.doi.org/10.5665/sleep.3222] [PMID: 24293763]

[213]
Rolinski, M.; Griffanti, L.; Piccini, P.; Roussakis, A.A.; Szewczyk-Krolikowski, K.; Menke, R.A.; Quinnell, T.; Zaiwalla, Z.; Klein, J.C.; Mackay, C.E.; Hu, M.T.M. Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson’s disease. Brain,  2016, 139(8), 2224-2234.
 [http://dx.doi.org/10.1093/brain/aww124] [PMID: 27297241]

[214]
Byun, J.I.; Kim, H.W.; Kang, H.; Cha, K.S.; Sunwoo, J.S.; Shin, J.W.; Moon, J.; Lee, S.T.; Jung, K.H.; Chu, K.; Kim, M.; Shin, W.C.; Lee, D.S.; Schenck, C.H.; Lee, S.K.; Jung, K.Y. Altered resting-state thalamo-occipital functional connectivity is associated with cognition in isolated rapid eye movement sleep behavior disorder. Sleep Med.,  2020, 69, 198-203.
 [http://dx.doi.org/10.1016/j.sleep.2020.01.010] [PMID: 32135454]

[215]
Li, G.; Zhou, L.; Chen, Z.; Luo, N.; Niu, M.; Li, Y.; Kang, W.; Liu, J. Dynamic functional connectivity impairments in idiopathic rapid eye movement sleep behavior disorder. Parkinsonism Relat. Disord.,  2020, 79, 11-17.
 [http://dx.doi.org/10.1016/j.parkreldis.2020.08.003] [PMID: 32858487]

[216]
Chen, Y.; Fan, C.; Yang, W.; Nie, K.; Wu, X.; Yang, Y.; Yang, Y.; Wang, L.; Zhang, Y.; Huang, B. Cortical hypoperfusion in patients with idiopathic rapid eye movement sleep behavior disorder detected with arterial spin-labeled perfusion MRI. Neurol. Sci.,  2020, 41(4), 809-815.
 [http://dx.doi.org/10.1007/s10072-019-04118-5] [PMID: 31792718]

[217]
Brück, A.; Aalto, S.; Rauhala, E.; Bergman, J.; Marttila, R.; Rinne, J.O. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov. Disord.,  2009, 24(7), 1009-1015.
 [http://dx.doi.org/10.1002/mds.22484] [PMID: 19260097]

[218]
Nandhagopal, R.; Kuramoto, L.; Schulzer, M.; Mak, E.; Cragg, J.; McKenzie, J.; McCormick, S.; Ruth, T.J.; Sossi, V.; de la Fuente-Fernandez, R.; Stoessl, A.J. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain,  2011, 134(11), 3290-3298.
 [http://dx.doi.org/10.1093/brain/awr233] [PMID: 22075521]

[219]
Jakobson Mo, S.; Linder, J.; Forsgren, L.; Holmberg, H.; Larsson, A.; Riklund, K. Pre- and postsynaptic dopamine SPECT in idiopathic Parkinsonian diseases: a follow-up study. BioMed Res. Int.,  2013, 2013, 1-14.
 [http://dx.doi.org/10.1155/2013/143532] [PMID: 24163811]

[220]
Marek, K.; Innis, R.; van Dyck, C.; Fussell, B.; Early, M.; Eberly, S.; Oakes, D.; Seibyl, J. [123I] -CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology,  2001, 57(11), 2089-2094.
 [http://dx.doi.org/10.1212/WNL.57.11.2089] [PMID: 11739831]

[221]
Pirker, W.; Djamshidian, S.; Asenbaum, S.; Gerschlager, W.; Tribl, G.; Hoffmann, M.; Brücke, T. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: A longitudinal β-CIT SPECT study. Mov. Disord.,  2002, 17(1), 45-53.
 [http://dx.doi.org/10.1002/mds.1265] [PMID: 11835438]

[222]
Nocker, M.; Seppi, K.; Donnemiller, E.; Virgolini, I.; Wenning, G.K.; Poewe, W.; Scherfler, C. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging,  2012, 39(6), 1012-1020.
 [http://dx.doi.org/10.1007/s00259-012-2100-5] [PMID: 22460689]

[223]
Sakakibara, S.; Hashimoto, R.; Katayama, T.; Kenjyo, M.; Yokokawa, Y.; Saito, Y.; Hirakawa, A.; Ito, M.; Nakamura, T.; Hara, K.; Hashizume, A.; Aiba, I.; Inukai, A.; Katsuno, M. Longitudinal change of DAT SPECT in Parkinson’s Disease and multiple system atrophy. J. Parkinsons Dis.,  2020, 10(1), 123-130.
 [http://dx.doi.org/10.3233/JPD-191710] [PMID: 31707374]

[224]
Schwarz, J.; Storch, A.; Koch, W.; Pogarell, O.; Radau, P.E.; Tatsch, K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J. Nucl. Med.,  2004, 45(10), 1694-1697.
 [PMID: 15471835]

[225]
Simuni, T.; Siderowf, A.; Lasch, S.; Coffey, C.S.; Caspell-Garcia, C.; Jennings, D.; Tanner, C.M.; Trojanowski, J.Q.; Shaw, L.M.; Seibyl, J.; Schuff, N.; Singleton, A.; Kieburtz, K.; Toga, A.W.; Mollenhauer, B.; Galasko, D.; Chahine, L.M.; Weintraub, D.; Foroud, T.; Tosun, D.; Poston, K.; Arnedo, V.; Frasier, M.; Sherer, T.; Chowdhury, S.; Marek, K. Longitudinal change of clinical and biological measures in early Parkinson’s disease: Parkinson’s progression markers initiative cohort. Mov. Disord.,  2018, 33(5), 771-782.
 [http://dx.doi.org/10.1002/mds.27361] [PMID: 29572948]

[226]
Huang, C.; Tang, C.; Feigin, A.; Lesser, M.; Ma, Y.; Pourfar, M.; Dhawan, V.; Eidelberg, D. Changes in network activity with the progression of Parkinson’s disease. Brain,  2007, 130(7), 1834-1846.
 [http://dx.doi.org/10.1093/brain/awm086] [PMID: 17470495]

[227]
Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Lang, A.; Olanow, C.W.; Tanner, C.; Marek, K. Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.,  2004, 351(24), 2498-2508.
 [http://dx.doi.org/10.1056/NEJMoa033447] [PMID: 15590952]

[228]
Merchant, K.M.; Cedarbaum, J.M.; Brundin, P.; Dave, K.D.; Eberling, J.; Espay, A.J.; Hutten, S.J.; Javidnia, M.; Luthman, J.; Maetzler, W.; Menalled, L.; Reimer, A.N.; Stoessl, A.J.; Weiner, D.M. The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group. A proposed roadmap for Parkinson’s disease proof of concept clinical trials investigating compounds targeting alpha-synuclein. J. Parkinsons Dis.,  2019, 9(1), 31-61.
 [http://dx.doi.org/10.3233/JPD-181471] [PMID: 30400107]

[229]
Lyoo, C.H.; Jeong, Y.; Ryu, Y.H.; Lee, S.Y.; Song, T.J.; Lee, J.H.; Rinne, J.O.; Lee, M.S. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain,  2008, 131(2), 438-446.
 [http://dx.doi.org/10.1093/brain/awm328] [PMID: 18178568]

[230]
Lee, P.H.; Kim, J.W.; Bang, O.Y.; Ahn, Y.H.; Joo, I.S.; Huh, K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin. Pharmacol. Ther.,  2008, 83(5), 723-730.
 [http://dx.doi.org/10.1038/sj.clpt.6100386] [PMID: 17898702]

[231]
Korat, Š.; Bidesi, N.S.R.; Bonanno, F.; Di Nanni, A.; Hoàng, A.N.N.; Herfert, K.; Maurer, A.; Battisti, U.M.; Bowden, G.D.; Thonon, D.; Vugts, D.; Windhorst, A.D.; Herth, M.M. Alpha-synuclein PET tracer development—an overview about current efforts. Pharmaceuticals,  2021, 14(9), 847.
 [http://dx.doi.org/10.3390/ph14090847] [PMID: 34577548]

[232]
Strohäker, T.; Jung, B.C.; Liou, S.H.; Fernandez, C.O.; Riedel, D.; Becker, S.; Halliday, G.M.; Bennati, M.; Kim, W.S.; Lee, S.J.; Zweckstetter, M. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nat. Commun.,  2019, 10(1), 5535.
 [http://dx.doi.org/10.1038/s41467-019-13564-w] [PMID: 31797870]

[233]
Van der Perren, A.; Gelders, G.; Fenyi, A.; Bousset, L.; Brito, F.; Peelaerts, W.; Van den Haute, C.; Gentleman, S.; Melki, R.; Baekelandt, V. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol.,  2020, 139(6), 977-1000.
 [http://dx.doi.org/10.1007/s00401-020-02157-3] [PMID: 32356200]

[234]
Kuebler, L.; Buss, S.; Leonov, A.; Ryazanov, S.; Schmidt, F.; Maurer, A.; Weckbecker, D.; Landau, A.M.; Lillethorup, T.P.; Bleher, D.; Saw, R.S.; Pichler, B.J.; Griesinger, C.; Giese, A.; Herfert, K. [11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates. Eur. J. Nucl. Med. Mol. Imaging,  2021, 48(6), 1759-1772.
 [http://dx.doi.org/10.1007/s00259-020-05133-x] [PMID: 33369690]

[235]
Deeg, A.A.; Reiner, A.M.; Schmidt, F.; Schueder, F.; Ryazanov, S.; Ruf, V.C.; Giller, K.; Becker, S.; Leonov, A.; Griesinger, C.; Giese, A.; Zinth, W. Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates. Biochim. Biophys. Acta, Gen. Subj.,  2015, 1850(9), 1884-1890.
 [http://dx.doi.org/10.1016/j.bbagen.2015.05.021] [PMID: 26028294]

[236]
Heras-Garvin, A.; Weckbecker, D.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G.K.; Stefanova, N. Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov. Disord.,  2019, 34(2), 255-263.
 [http://dx.doi.org/10.1002/mds.27562] [PMID: 30452793]

[237]
Frey, K.A. Molecular imaging of extrapyramidal movement disorders with dementia: The 4R tauopathies. Semin. Nucl. Med.,  2021, 51(3), 275-285.
 [http://dx.doi.org/10.1053/j.semnuclmed.2020.12.003] [PMID: 33431202]

[238]
Whitwell, J.L.; Tosakulwong, N.; Schwarz, C.G.; Botha, H.; Senjem, M.L.; Spychalla, A.J.; Ahlskog, J.E.; Knopman, D.S.; Petersen, R.C.; Jack, C.R., Jr; Lowe, V.J.; Josephs, K.A. MRI Outperforms [18F]AV‐1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov. Disord.,  2019, 34(1), 105-113.
 [http://dx.doi.org/10.1002/mds.27546] [PMID: 30468693]

[239]
Lowe, V.J.; Curran, G.; Fang, P.; Liesinger, A.M.; Josephs, K.A.; Parisi, J.E.; Kantarci, K.; Boeve, B.F.; Pandey, M.K.; Bruinsma, T.; Knopman, D.S.; Jones, D.T.; Petrucelli, L.; Cook, C.N.; Graff-Radford, N.R.; Dickson, D.W.; Petersen, R.C.; Jack, C.R., Jr; Murray, M.E. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun.,  2016, 4(1), 58.
 [http://dx.doi.org/10.1186/s40478-016-0315-6] [PMID: 27296779]

[240]
Okamura, N.; Harada, R.; Ishiki, A.; Kikuchi, A.; Nakamura, T.; Kudo, Y. The development and validation of tau PET tracers: Current status and future directions. Clin. Transl. Imaging,  2018, 6(4), 305-316.
 [http://dx.doi.org/10.1007/s40336-018-0290-y] [PMID: 30148121]

[241]
Coakeley, S.; Cho, S.S.; Koshimori, Y.; Rusjan, P.; Ghadery, C.; Kim, J.; Lang, A.E.; Houle, S.; Strafella, A.P. [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Struct. Funct.,  2018, 223(2), 589-595.
 [http://dx.doi.org/10.1007/s00429-017-1507-y] [PMID: 28884232]

[242]
Hansen, A.K.; Knudsen, K.; Lillethorup, T.P.; Landau, A.M.; Parbo, P.; Fedorova, T.; Audrain, H.; Bender, D.; Østergaard, K.; Brooks, D.J.; Borghammer, P. In vivo imaging of neuromelanin in Parkinson’s disease using 18 F-AV-1451 PET. Brain,  2016, 139(7), 2039-2049.
 [http://dx.doi.org/10.1093/brain/aww098] [PMID: 27190023]

[243]
Goedert, M.; Spillantini, M.G.; Cairns, N.J.; Crowther, R.A. Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron,  1992, 8(1), 159-168.
 [http://dx.doi.org/10.1016/0896-6273(92)90117-V] [PMID: 1530909]

[244]
Flament, S.; Delacourte, A.; Verny, M.; Hauw, J.J.; Javoy-Agid, F. Abnormal Tau proteins in progressive supranuclear palsy. Acta Neuropathol.,  1991, 81(6), 591-596.
 [http://dx.doi.org/10.1007/BF00296367] [PMID: 1831952]

[245]
Ksiezak-Reding, H.; Morgan, K.; Mattiace, L.A.; Davies, P.; Liu, W.K.; Yen, S.H.; Weidenheim, K.; Dickson, D.W. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am. J. Pathol.,  1994, 145(6), 1496-1508.
 [PMID: 7992852]

[246]
Ono, M.; Sahara, N.; Kumata, K.; Ji, B.; Ni, R.; Koga, S.; Dickson, D.W.; Trojanowski, J.Q.; Lee, V.M.Y.; Yoshida, M.; Hozumi, I.; Yoshiyama, Y.; van Swieten, J.C.; Nordberg, A.; Suhara, T.; Zhang, M.R.; Higuchi, M. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain,  2017, 140(3), aww339.
 [http://dx.doi.org/10.1093/brain/aww339] [PMID: 28087578]

[247]
Gaurav, R.; Yahia-Cherif, L.; Pyatigorskaya, N.; Mangone, G.; Biondetti, E.; Valabrègue, R.; Ewenczyk, C.; Hutchison, R.M.; Cedarbaum, J.M.; Corvol, J.C.; Vidailhet, M.; Lehéricy, S. Longitudinal changes in neuromelanin MRI Signal in Parkinson’s Disease: A progression marker. Mov. Disord.,  2021, 36(7), 1592-1602.
 [http://dx.doi.org/10.1002/mds.28531] [PMID: 33751655]

[248]
Matsuura, K.; Maeda, M.; Tabei, K.; Umino, M.; Kajikawa, H.; Satoh, M.; Kida, H.; Tomimoto, H. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci. Lett.,  2016, 633, 112-117.
 [http://dx.doi.org/10.1016/j.neulet.2016.09.011] [PMID: 27619539]

[249]
Arpin, D.J.; Mitchell, T.; Archer, D.B.; Burciu, R.G.; Chu, W.T.; Gao, H.; Guttuso, T.; Hess, C.W.; Lai, S.; Malaty, I.A.; McFarland, N.R.; Pasternak, O.; Price, C.C.; Shukla, A.W.; Wu, S.S.; Okun, M.S.; Vaillancourt, D.E. Diffusion magnetic resonance imaging detects progression in Parkinson’s disease: A placebo-controlled trial of rasagiline. Mov. Disord.,  2022, 37(2), 325-333.
 [PMID: 34724257]

[250]
Vaillancourt, D.E.; Mitchell, T. Parkinson’s disease progression in the substantia nigra: Location, location, location. Brain,  2020, 143(9), 2628-2630.
 [http://dx.doi.org/10.1093/brain/awaa252] [PMID: 32947614]

[251]
Chung, J.W.; Burciu, R.G.; Ofori, E.; Shukla, P.; Okun, M.S.; Hess, C.W.; Vaillancourt, D.E. Parkinson’s disease diffusion MRI is not affected by acute antiparkinsonian medication. Neuroimage Clin.,  2017, 14, 417-421.
 [http://dx.doi.org/10.1016/j.nicl.2017.02.012] [PMID: 28275542]

[252]
Caso, F.; Agosta, F.; Ječmenica-Lukić, M.; Petrović, I.; Meani, A.; Kostic, V.S.; Filippi, M. Progression of white matter damage in progressive supranuclear palsy with predominant parkinsonism. Parkinsonism Relat. Disord.,  2018, 49, 95-99.
 [http://dx.doi.org/10.1016/j.parkreldis.2018.01.001] [PMID: 29336906]

[253]
Reginold, W.; Lang, A.E.; Marras, C.; Heyn, C.; Alharbi, M.; Mikulis, D.J. Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat. Disord.,  2014, 20(2), 222-225.
 [http://dx.doi.org/10.1016/j.parkreldis.2013.10.002] [PMID: 24239142]

[254]
Zhang, Y.; Walter, R.; Ng, P.; Luong, P.N.; Dutt, S.; Heuer, H.; Rojas-Rodriguez, J.C.; Tsai, R.; Litvan, I.; Dickerson, B.C.; Tartaglia, M.C.; Rabinovici, G.; Miller, B.L.; Rosen, H.J.; Schuff, N.; Boxer, A.L. Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: A longitudinal diffusion tensor imaging study. PLoS One,  2016, 11(6), e0157218.
 [http://dx.doi.org/10.1371/journal.pone.0157218] [PMID: 27310132]

[255]
Hanganu, A.; Bedetti, C.; Degroot, C.; Mejia-Constain, B.; Lafontaine, A.L.; Soland, V.; Chouinard, S.; Bruneau, M.A.; Mellah, S.; Belleville, S.; Monchi, O. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain,  2014, 137(4), 1120-1129.
 [http://dx.doi.org/10.1093/brain/awu036] [PMID: 24613932]

[256]
Mak, E.; Su, L.; Williams, G.B.; Firbank, M.J.; Lawson, R.A.; Yarnall, A.J.; Duncan, G.W.; Owen, A.M.; Khoo, T.K.; Brooks, D.J.; Rowe, J.B.; Barker, R.A.; Burn, D.J.; O’Brien, J.T. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain,  2015, 138(10), 2974-2986.
 [http://dx.doi.org/10.1093/brain/awv211] [PMID: 26173861]

[257]
Ibarretxe-Bilbao, N.; Junque, C.; Segura, B.; Baggio, H.C.; Marti, M.J.; Valldeoriola, F.; Bargallo, N.; Tolosa, E. Progression of cortical thinning in early Parkinson’s disease. Mov. Disord.,  2012, 27(14), 1746-1753.
 [http://dx.doi.org/10.1002/mds.25240] [PMID: 23124622]

[258]
Yau, Y.; Zeighami, Y.; Baker, T.E.; Larcher, K.; Vainik, U.; Dadar, M.; Fonov, V.S.; Hagmann, P.; Griffa, A.; Mišić, B.; Collins, D.L.; Dagher, A. Network connectivity determines cortical thinning in early Parkinson’s disease progression. Nat. Commun.,  2018, 9(1), 12.
 [http://dx.doi.org/10.1038/s41467-017-02416-0] [PMID: 29295991]

[259]
Campabadal, A.; Uribe, C.; Segura, B.; Baggio, H.C.; Abos, A.; Garcia-Diaz, A.I.; Marti, M.J.; Valldeoriola, F.; Compta, Y.; Bargallo, N.; Junque, C. Brain correlates of progressive olfactory loss in Parkinson’s disease. Parkinsonism Relat. Disord.,  2017, 41, 44-50.
 [http://dx.doi.org/10.1016/j.parkreldis.2017.05.005] [PMID: 28522171]

[260]
Sterling, N.W.; Wang, M.; Zhang, L.; Lee, E.Y.; Du, G.; Lewis, M.M.; Styner, M.; Huang, X. Stage-dependent loss of cortical gyrification as Parkinson disease “unfolds”. Neurology,  2016, 86(12), 1143-1151.
 [http://dx.doi.org/10.1212/WNL.0000000000002492] [PMID: 26888982]

[261]
Dutt, S.; Binney, R.J.; Heuer, H.W.; Luong, P.; Attygalle, S.; Bhatt, P.; Marx, G.A.; Elofson, J.; Tartaglia, M.C.; Litvan, I.; McGinnis, S.M.; Dickerson, B.C.; Kornak, J.; Waltzman, D.; Voltarelli, L.; Schuff, N.; Rabinovici, G.D.; Kramer, J.H.; Jack, C.R., Jr; Miller, B.L.; Rosen, H.J.; Boxer, A.L. AL-108-231 investigators. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology,  2016, 87(19), 2016-2025.
 [http://dx.doi.org/10.1212/WNL.0000000000003305] [PMID: 27742814]

[262]
Südmeyer, M.; Pieperhoff, P.; Ferrea, S.; Krause, H.; Groiss, S.J.; Elben, S.; Wojtecki, L.; Zilles, K.; Amunts, K.; Schnitzler, A. Longitudinal deformation-based morphometry reveals spatio-temporal dynamics of brain volume changes in patients with corticobasal syndrome. PLoS One,  2012, 7(7), e41873.
 [http://dx.doi.org/10.1371/journal.pone.0041873] [PMID: 22848644]

[263]
Agosta, F.; Caso, F.; Ječmenica-Lukić, M.; Petrović, I.N.; Valsasina, P.; Meani, A.; Copetti, M.; Kostić, V.S.; Filippi, M. Tracking brain damage in progressive supranuclear palsy: A longitudinal MRI study. J. Neurol. Neurosurg. Psychiatry,  2018, 89(7), 696-701.
 [http://dx.doi.org/10.1136/jnnp-2017-317443] [PMID: 29348302]

[264]
Paviour, D.C.; Price, S.L.; Jahanshahi, M.; Lees, A.J.; Fox, N.C. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain,  2006, 129(4), 1040-1049.
 [http://dx.doi.org/10.1093/brain/awl021] [PMID: 16455792]

[265]
Minnerop, M.; Lüders, E.; Specht, K.; Ruhlmann, J.; Schimke, N.; Thompson, P.M.; Chou, Y.Y.; Toga, A.W.; Abele, M.; Wüllner, U.; Klockgether, T. Callosal tissue loss in multiple system atrophy-A one-year follow-up study. Mov. Disord.,  2010, 25(15), 2613-2620.
 [http://dx.doi.org/10.1002/mds.23318] [PMID: 20623690]

[266]
Quattrone, A.; Morelli, M.; Quattrone, A.; Vescio, B.; Nigro, S.; Arabia, G.; Nisticò, R.; Novellino, F.; Salsone, M.; Arcuri, P.; Luca, A.; Mazzuca, A.; Alessio, C.; Rocca, F.; Caracciolo, M. Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study. Parkinsonism Relat. Disord.,  2020, 72, 1-6.
 [http://dx.doi.org/10.1016/j.parkreldis.2020.01.019] [PMID: 32036297]

[267]
Nigro, S.; Morelli, M.; Arabia, G.; Nisticò, R.; Novellino, F.; Salsone, M.; Rocca, F.; Quattrone, A. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease? Parkinsonism Relat. Disord.,  2017, 41, 31-36.
 [http://dx.doi.org/10.1016/j.parkreldis.2017.05.002] [PMID: 28487107]
Rights & Permissions Print Cite
Article Metrics
36
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1570159X21666230801140648	Print ISSN 1570-159X
Publisher Name Bentham Science Publisher	Online ISSN 1875-6190
Current Neuropharmacology

Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?

Abstract

Graphical Abstract

Advances in paediatric and adult brain cancers: emerging targets and treatments

Emotion (dys)regulation: an integration of pharmacological, neurobiological and psychologicalframeworks

Intercellular Communications in cerebral ischemia

Microbiota- Gut - Brain Axis in mood and neuropsychiatric disorders. Therapeutic opportunities

Current Neuropharmacology

Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?

Abstract

Graphical Abstract

Call for Papers in Thematic Issues

Advances in paediatric and adult brain cancers: emerging targets and treatments

Emotion (dys)regulation: an integration of pharmacological, neurobiological and psychologicalframeworks

Intercellular Communications in cerebral ischemia

Microbiota- Gut - Brain Axis in mood and neuropsychiatric disorders. Therapeutic opportunities

Related Journals

Related Books

Related Articles
